{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "path = \"mds_case/payloads.jsonl\"\n",
    "data = pd.read_json(path, lines=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>utn</th>\n",
       "      <th>phase</th>\n",
       "      <th>title</th>\n",
       "      <th>gender</th>\n",
       "      <th>language</th>\n",
       "      <th>studies_id</th>\n",
       "      <th>study_type</th>\n",
       "      <th>maximum_age</th>\n",
       "      <th>minimum_age</th>\n",
       "      <th>interventions</th>\n",
       "      <th>...</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>countries_and_sites</th>\n",
       "      <th>publications</th>\n",
       "      <th>eligibility</th>\n",
       "      <th>additional_info</th>\n",
       "      <th>references</th>\n",
       "      <th>location</th>\n",
       "      <th>ctgov_location</th>\n",
       "      <th>duplicate_info</th>\n",
       "      <th>mesh_terms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05680818</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>CALIBRATE: A Phase 3, Randomized, Open-Label S...</td>\n",
       "      <td>All</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>16 Years</td>\n",
       "      <td>[{'type': 'DRUG', 'name': 'Encaleret', 'descri...</td>\n",
       "      <td>...</td>\n",
       "      <td>ADH1 is a rare genetic form of hypoparathyroid...</td>\n",
       "      <td>[{'country_start': None, 'country_end': None, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'inclusion': 'Key Inclusion Criteria:\n",
       "\n",
       "1. Par...</td>\n",
       "      <td>{'sponsors': [{'name': 'Calcilytix Therapeutic...</td>\n",
       "      <td>[{'url': 'https://clinicaltrials.gov/study/NCT...</td>\n",
       "      <td>[{'facility': 'UCSF Benioff Children's Hospita...</td>\n",
       "      <td>[{'facility': 'UCSF Benioff Children's Hospita...</td>\n",
       "      <td>{'nctId': 'NCT05680818', 'orgStudyIdInfo': {'i...</td>\n",
       "      <td>[{'id': 'D000001176', 'term': 'Arthrogryposis'...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT06061146</td>\n",
       "      <td>[Phase 2]</td>\n",
       "      <td>Tislelizumab Combined With Concurrent Chemorad...</td>\n",
       "      <td>All</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>90 Years</td>\n",
       "      <td>70 Years</td>\n",
       "      <td>[{'type': 'DRUG', 'name': 'Arm A', 'descriptio...</td>\n",
       "      <td>...</td>\n",
       "      <td>None</td>\n",
       "      <td>[{'country_start': None, 'country_end': None, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Volunte...</td>\n",
       "      <td>{'sponsors': [{'name': 'Tianjin Medical Univer...</td>\n",
       "      <td>[{'url': 'https://clinicaltrials.gov/study/NCT...</td>\n",
       "      <td>[{'facility': 'Tianjin Cancer Hospital', 'stat...</td>\n",
       "      <td>[{'facility': 'Tianjin Cancer Hospital', 'stat...</td>\n",
       "      <td>{'nctId': 'NCT06061146', 'orgStudyIdInfo': {'i...</td>\n",
       "      <td>[{'id': 'D000004938', 'term': 'Esophageal Neop...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02935257</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>Immunotherapy for High Risk/Relapsed CD19+ Acu...</td>\n",
       "      <td>All</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>16 Years</td>\n",
       "      <td>[{'type': 'BIOLOGICAL', 'name': 'CD19CAT-41BBZ...</td>\n",
       "      <td>...</td>\n",
       "      <td>This is a multi-centre, non-randomised, open l...</td>\n",
       "      <td>[{'country_start': None, 'country_end': None, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Age ≥16...</td>\n",
       "      <td>{'sponsors': [{'name': 'University College, Lo...</td>\n",
       "      <td>[{'url': 'https://clinicaltrials.gov/study/NCT...</td>\n",
       "      <td>[{'facility': 'University College London Hospi...</td>\n",
       "      <td>[{'facility': 'University College London Hospi...</td>\n",
       "      <td>{'nctId': 'NCT02935257', 'orgStudyIdInfo': {'i...</td>\n",
       "      <td>[{'id': 'D000008223', 'term': 'Lymphoma'}, {'i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04137653</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>Treatment of Triple-negative Breast Cancer Wit...</td>\n",
       "      <td>Female</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>70 Years</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>[{'type': 'DRUG', 'name': 'nab-Paclitaxel+carb...</td>\n",
       "      <td>...</td>\n",
       "      <td>Breast cancer has been one of the most common ...</td>\n",
       "      <td>[{'country_start': None, 'country_end': None, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'inclusion': 'Inclusion Criteria:\n",
       "\n",
       " - breast ...</td>\n",
       "      <td>{'sponsors': [{'name': 'Shengjing Hospital', '...</td>\n",
       "      <td>[{'url': 'https://clinicaltrials.gov/study/NCT...</td>\n",
       "      <td>[{'facility': 'Shengjing Hospital of China Med...</td>\n",
       "      <td>[{'facility': 'Shengjing Hospital of China Med...</td>\n",
       "      <td>{'nctId': 'NCT04137653', 'orgStudyIdInfo': {'i...</td>\n",
       "      <td>[{'id': 'D000001943', 'term': 'Breast Neoplasm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05809414</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>Amantadine and Transcranial Magnetic Stimulati...</td>\n",
       "      <td>All</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>None</td>\n",
       "      <td>18 Years</td>\n",
       "      <td>[{'type': 'DEVICE', 'name': 'Transcranial Magn...</td>\n",
       "      <td>...</td>\n",
       "      <td>Multiple Sclerosis (MS) is the most frequent c...</td>\n",
       "      <td>[{'country_start': None, 'country_end': None, ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Expande...</td>\n",
       "      <td>{'sponsors': [{'name': 'Hospital San Carlos, M...</td>\n",
       "      <td>[{'url': 'https://clinicaltrials.gov/study/NCT...</td>\n",
       "      <td>[{'facility': 'Hospital Puerta del Mar', 'stat...</td>\n",
       "      <td>[{'facility': 'Hospital Puerta del Mar', 'stat...</td>\n",
       "      <td>{'nctId': 'NCT05809414', 'orgStudyIdInfo': {'i...</td>\n",
       "      <td>[{'id': 'D000009103', 'term': 'Multiple Sclero...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           utn      phase                                              title  \\\n",
       "0  NCT05680818  [Phase 3]  CALIBRATE: A Phase 3, Randomized, Open-Label S...   \n",
       "1  NCT06061146  [Phase 2]  Tislelizumab Combined With Concurrent Chemorad...   \n",
       "2  NCT02935257  [Phase 1]  Immunotherapy for High Risk/Relapsed CD19+ Acu...   \n",
       "3  NCT04137653  [Phase 3]  Treatment of Triple-negative Breast Cancer Wit...   \n",
       "4  NCT05809414  [Phase 3]  Amantadine and Transcranial Magnetic Stimulati...   \n",
       "\n",
       "   gender  language  studies_id  study_type maximum_age minimum_age  \\\n",
       "0     All       NaN         NaN         NaN        None    16 Years   \n",
       "1     All       NaN         NaN         NaN    90 Years    70 Years   \n",
       "2     All       NaN         NaN         NaN        None    16 Years   \n",
       "3  Female       NaN         NaN         NaN    70 Years    18 Years   \n",
       "4     All       NaN         NaN         NaN        None    18 Years   \n",
       "\n",
       "                                       interventions  ...  \\\n",
       "0  [{'type': 'DRUG', 'name': 'Encaleret', 'descri...  ...   \n",
       "1  [{'type': 'DRUG', 'name': 'Arm A', 'descriptio...  ...   \n",
       "2  [{'type': 'BIOLOGICAL', 'name': 'CD19CAT-41BBZ...  ...   \n",
       "3  [{'type': 'DRUG', 'name': 'nab-Paclitaxel+carb...  ...   \n",
       "4  [{'type': 'DEVICE', 'name': 'Transcranial Magn...  ...   \n",
       "\n",
       "                                detailed_description  \\\n",
       "0  ADH1 is a rare genetic form of hypoparathyroid...   \n",
       "1                                               None   \n",
       "2  This is a multi-centre, non-randomised, open l...   \n",
       "3  Breast cancer has been one of the most common ...   \n",
       "4  Multiple Sclerosis (MS) is the most frequent c...   \n",
       "\n",
       "                                 countries_and_sites publications  \\\n",
       "0  [{'country_start': None, 'country_end': None, ...           []   \n",
       "1  [{'country_start': None, 'country_end': None, ...           []   \n",
       "2  [{'country_start': None, 'country_end': None, ...           []   \n",
       "3  [{'country_start': None, 'country_end': None, ...           []   \n",
       "4  [{'country_start': None, 'country_end': None, ...           []   \n",
       "\n",
       "                                         eligibility  \\\n",
       "0  {'inclusion': 'Key Inclusion Criteria:\n",
       "\n",
       "1. Par...   \n",
       "1  {'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Volunte...   \n",
       "2  {'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Age ≥16...   \n",
       "3  {'inclusion': 'Inclusion Criteria:\n",
       "\n",
       " - breast ...   \n",
       "4  {'inclusion': 'Inclusion Criteria:\n",
       "\n",
       "1. Expande...   \n",
       "\n",
       "                                     additional_info  \\\n",
       "0  {'sponsors': [{'name': 'Calcilytix Therapeutic...   \n",
       "1  {'sponsors': [{'name': 'Tianjin Medical Univer...   \n",
       "2  {'sponsors': [{'name': 'University College, Lo...   \n",
       "3  {'sponsors': [{'name': 'Shengjing Hospital', '...   \n",
       "4  {'sponsors': [{'name': 'Hospital San Carlos, M...   \n",
       "\n",
       "                                          references  \\\n",
       "0  [{'url': 'https://clinicaltrials.gov/study/NCT...   \n",
       "1  [{'url': 'https://clinicaltrials.gov/study/NCT...   \n",
       "2  [{'url': 'https://clinicaltrials.gov/study/NCT...   \n",
       "3  [{'url': 'https://clinicaltrials.gov/study/NCT...   \n",
       "4  [{'url': 'https://clinicaltrials.gov/study/NCT...   \n",
       "\n",
       "                                            location  \\\n",
       "0  [{'facility': 'UCSF Benioff Children's Hospita...   \n",
       "1  [{'facility': 'Tianjin Cancer Hospital', 'stat...   \n",
       "2  [{'facility': 'University College London Hospi...   \n",
       "3  [{'facility': 'Shengjing Hospital of China Med...   \n",
       "4  [{'facility': 'Hospital Puerta del Mar', 'stat...   \n",
       "\n",
       "                                      ctgov_location  \\\n",
       "0  [{'facility': 'UCSF Benioff Children's Hospita...   \n",
       "1  [{'facility': 'Tianjin Cancer Hospital', 'stat...   \n",
       "2  [{'facility': 'University College London Hospi...   \n",
       "3  [{'facility': 'Shengjing Hospital of China Med...   \n",
       "4  [{'facility': 'Hospital Puerta del Mar', 'stat...   \n",
       "\n",
       "                                      duplicate_info  \\\n",
       "0  {'nctId': 'NCT05680818', 'orgStudyIdInfo': {'i...   \n",
       "1  {'nctId': 'NCT06061146', 'orgStudyIdInfo': {'i...   \n",
       "2  {'nctId': 'NCT02935257', 'orgStudyIdInfo': {'i...   \n",
       "3  {'nctId': 'NCT04137653', 'orgStudyIdInfo': {'i...   \n",
       "4  {'nctId': 'NCT05809414', 'orgStudyIdInfo': {'i...   \n",
       "\n",
       "                                          mesh_terms  \n",
       "0  [{'id': 'D000001176', 'term': 'Arthrogryposis'...  \n",
       "1  [{'id': 'D000004938', 'term': 'Esophageal Neop...  \n",
       "2  [{'id': 'D000008223', 'term': 'Lymphoma'}, {'i...  \n",
       "3  [{'id': 'D000001943', 'term': 'Breast Neoplasm...  \n",
       "4  [{'id': 'D000009103', 'term': 'Multiple Sclero...  \n",
       "\n",
       "[5 rows x 27 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.head()\n",
    "#data.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'inclusion': 'Key Inclusion Criteria:\\n\\n1. Participants must have a documented pathogenic or likely pathogenic activating variant, or variant of uncertain significance, of the calcium sensing receptor (CASR) gene associated with biochemical findings of hypoparathyroidism.\\n2. Participants must have a documented history of symptoms or signs of ADH1.\\n3. Participants 16 to <18 years old must have closed growth plates on hand radiograph.\\n4. Participants treated with thiazide diuretics must discontinue thiazides for at least 14 days prior to SoC Optimization Visit 1 through Week 24 (Period 3). When the thiazide is being used as an antihypertensive, alternative therapy will be prescribed by the Investigator as needed.\\n5. Participants treated with phosphate binders must discontinue the phosphate binders at least one day prior to the SoC Optimization Visit 1.\\n6. Participants treated with magnesium or potassium supplements must be willing to discontinue such treatment prior to the first dose of encaleret.\\n7. Participants treated with potassium-sparing diuretics must be willing to discontinue such treatment prior to the first dose of encaleret.\\n8. Participants must meet SoC Optimization criteria as defined in the protocol.\\n\\nKey Exclusion Criteria:\\n\\n1. History of hypocalcemic seizure within the past 3 months preceding Screening.\\n2. History of thyroid or parathyroid surgery.\\n3. History of renal transplantation.\\n4. Pregnant or nursing (lactating) women, where pregnancy is confirmed by a positive beta-human chorionic gonadotropin (β-hCG) laboratory test.\\n5. History of treatment with parathyroid hormone (PTH) 1-84 or 1-34 within the 2 months preceding Screening and requiring SoC doses exceeding >1.2× their pre-PTH treatment total daily doses or bone turnover markers, Collagen cross-linked C-telopeptide (CTx )and Procollagen type 1 N-propeptide (P1NP), > upper limit of normal for sex, age (men only) and menopausal status (women only).\\n6. Blood 25-OH Vitamin D level <25 nanograms (ng)/milliliter (mL).\\n7. Estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m^2 using chronic kidney disease-EPI creatinine equation refit without the race variable (chronic kidney disease-EPI creatinine equation refit without the race variable [CKD-EPIcr_R]) (for participants <18 years old the Bedside Schwartz equation should be used).\\n8. Participants with positive Hepatitis B surface antigen (HBsAg), Hepatitis A immunoglobulin M (IgM), or human immunodeficiency virus (HIV) viral serology test at the Screening Visit. Participants who are in complete remission from Hepatitis C virus (HCV) as evidenced by sensitive assay ≥12 weeks after completion of HCV therapy may participate in the study.\\n\\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.',\n",
       " 'exclusion': 'Key Inclusion Criteria:\\n\\n1. Participants must have a documented pathogenic or likely pathogenic activating variant, or variant of uncertain significance, of the calcium sensing receptor (CASR) gene associated with biochemical findings of hypoparathyroidism.\\n2. Participants must have a documented history of symptoms or signs of ADH1.\\n3. Participants 16 to <18 years old must have closed growth plates on hand radiograph.\\n4. Participants treated with thiazide diuretics must discontinue thiazides for at least 14 days prior to SoC Optimization Visit 1 through Week 24 (Period 3). When the thiazide is being used as an antihypertensive, alternative therapy will be prescribed by the Investigator as needed.\\n5. Participants treated with phosphate binders must discontinue the phosphate binders at least one day prior to the SoC Optimization Visit 1.\\n6. Participants treated with magnesium or potassium supplements must be willing to discontinue such treatment prior to the first dose of encaleret.\\n7. Participants treated with potassium-sparing diuretics must be willing to discontinue such treatment prior to the first dose of encaleret.\\n8. Participants must meet SoC Optimization criteria as defined in the protocol.\\n\\nKey Exclusion Criteria:\\n\\n1. History of hypocalcemic seizure within the past 3 months preceding Screening.\\n2. History of thyroid or parathyroid surgery.\\n3. History of renal transplantation.\\n4. Pregnant or nursing (lactating) women, where pregnancy is confirmed by a positive beta-human chorionic gonadotropin (β-hCG) laboratory test.\\n5. History of treatment with parathyroid hormone (PTH) 1-84 or 1-34 within the 2 months preceding Screening and requiring SoC doses exceeding >1.2× their pre-PTH treatment total daily doses or bone turnover markers, Collagen cross-linked C-telopeptide (CTx )and Procollagen type 1 N-propeptide (P1NP), > upper limit of normal for sex, age (men only) and menopausal status (women only).\\n6. Blood 25-OH Vitamin D level <25 nanograms (ng)/milliliter (mL).\\n7. Estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m^2 using chronic kidney disease-EPI creatinine equation refit without the race variable (chronic kidney disease-EPI creatinine equation refit without the race variable [CKD-EPIcr_R]) (for participants <18 years old the Bedside Schwartz equation should be used).\\n8. Participants with positive Hepatitis B surface antigen (HBsAg), Hepatitis A immunoglobulin M (IgM), or human immunodeficiency virus (HIV) viral serology test at the Screening Visit. Participants who are in complete remission from Hepatitis C virus (HCV) as evidenced by sensitive assay ≥12 weeks after completion of HCV therapy may participate in the study.\\n\\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.'}"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.eligibility[0]\n",
    "#Phase 1-3, sometimes \"early phase 1 -> phase 1\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "phase\n",
       "Phase 2           9129\n",
       "Phase 1           5641\n",
       "Phase 3           2739\n",
       "Not Applicable    1330\n",
       "Early Phase 1      509\n",
       "Phase 4            403\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Flatten the list of conditions and explode them into individual rows\n",
    "#phase_column = data.phase.dropna()\n",
    "conditions_count= data.phase.explode().value_counts()\n",
    "conditions_count"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "phase\n",
       "Phase 2           0.462204\n",
       "Phase 1           0.285606\n",
       "Phase 3           0.138677\n",
       "Not Applicable    0.067338\n",
       "Early Phase 1     0.025771\n",
       "Phase 4           0.020404\n",
       "Name: count, dtype: float64"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "conditions_count / sum(conditions_count)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                  [Autosomal Dominant Hypocalcemia (ADH)]\n",
       "1                                      [Esophageal Cancer]\n",
       "2               [Leukemia, Lymphoblastic, Acute, Lymphoma]\n",
       "3                                          [Breast Cancer]\n",
       "4                            [Multiple Sclerosis, Fatigue]\n",
       "                               ...                        \n",
       "17130    [Peripheral Artery Disease, Peripheral Vascula...\n",
       "17131    [Ischemic Stroke, Acute, TIA, Symptomatic Intr...\n",
       "17132    [Chronic Granulomatous Disease (CGD), X-Linked...\n",
       "17133                                        [Solid Tumor]\n",
       "17134                     [Progressive Pulmonary Fibrosis]\n",
       "Name: conditions, Length: 17135, dtype: object"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#What are the top 10 most commonly studied conditions (using only clinicaltrials.gov records)?\n",
    "\n",
    "data.conditions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "conditions\n",
      "Breast Cancer                 387\n",
      "Advanced Solid Tumor          362\n",
      "Solid Tumor                   297\n",
      "Multiple Myeloma              254\n",
      "Acute Myeloid Leukemia        242\n",
      "Gastric Cancer                241\n",
      "Hepatocellular Carcinoma      239\n",
      "Colorectal Cancer             237\n",
      "Ovarian Cancer                195\n",
      "Non-small Cell Lung Cancer    187\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "# Flatten the list of conditions and explode them into individual rows\n",
    "conditions_flattened = data['conditions'].explode()\n",
    "\n",
    "# Count the occurrences of each condition\n",
    "conditions_count = conditions_flattened.value_counts()\n",
    "\n",
    "# Select the top 10 conditions\n",
    "top_10_conditions = conditions_count.head(10)\n",
    "\n",
    "# Display the top 10 conditions\n",
    "print(top_10_conditions)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>profile</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>age</th>\n",
       "      <td>53</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>condition</th>\n",
       "      <td>Amyotrophic Lateral Sclerosis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>country</th>\n",
       "      <td>France</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>gender</th>\n",
       "      <td>Male</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>profile</th>\n",
       "      <td>Histology: None\\nPrevious treatment: riluzole ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                     profile\n",
       "age                                                       53\n",
       "condition                      Amyotrophic Lateral Sclerosis\n",
       "country                                               France\n",
       "gender                                                  Male\n",
       "profile    Histology: None\\nPrevious treatment: riluzole ..."
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Note: For Part 2, keep this dataset but keep only trials in Phase 1, 2 or 3.\n",
    "'''At myTomorrows, we index clinical trials against conditions ourselves, to improve the performance of our Search engine. Now, for three sample patients, we want to see what trials might be eligible for them.\n",
    "Please find the indexing record, as well as three sample patient records, in the Resources.\n",
    "'''\n",
    "\n",
    "patient_1 = pd.read_json(\"mds_case/patient_01.json\")\n",
    "patient_2 = pd.read_json(\"mds_case/patient_02.json\")\n",
    "patient_3 = pd.read_json(\"mds_case/patient_03.json\")\n",
    "\n",
    "patient_1.head()\n",
    "#patient_1.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Histology: None\\nPrevious treatment: riluzole since two months\\nBiomarkers: SOD1 mutation\\nTests: None\\nComorbidities: rheumatoid arthritis\\nOther: None'"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "patient_1['profile'].profile"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['utn', 'phase', 'title', 'gender', 'language', 'studies_id',\n",
       "       'study_type', 'maximum_age', 'minimum_age', 'interventions',\n",
       "       'protocol_type', 'overall_status', 'primary_purpose', 'conditions',\n",
       "       'start_date', 'end_date', 'brief_summary', 'detailed_description',\n",
       "       'countries_and_sites', 'publications', 'eligibility', 'additional_info',\n",
       "       'references', 'location', 'ctgov_location', 'duplicate_info',\n",
       "       'mesh_terms'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "\n",
    "def fetch_studies(query):\n",
    "    url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "    headers = {\n",
    "        \"accept\": \"application/json\"\n",
    "    }\n",
    "    params = {\n",
    "        \"query.cond\": query\n",
    "    }\n",
    "    response = requests.get(url, headers=headers, params=params)\n",
    "    if response.status_code == 200:\n",
    "        return response.json()  # Return the JSON response if successful\n",
    "    else:\n",
    "        return response.status_code  # Return the HTTP status code if not successful\n",
    "\n",
    "#query = \"Amyotrophic Lateral Sclerosis\"\n",
    "#result = fetch_studies(query)\n",
    "#print(result)\n",
    "\n",
    "\n",
    "def find_eligable_studies(patient):\n",
    "    condition = patient['profile'].condition\n",
    "    eligable_studies = fetch_studies(condition)\n",
    "    amount_studies = len(eligable_studies['studies'])\n",
    "    return amount_studies, eligable_studies\n",
    "\n",
    "\n",
    "amount_s, studies = find_eligable_studies(patient_1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT05105958', 'orgStudyIdInfo': {'id': 'TIDALS_01'}, 'organization': {'fullName': 'University Hospital, Geneva', 'class': 'OTHER'}, 'briefTitle': 'Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis', 'officialTitle': 'Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (TIDALS): a Randomized Placebo-controlled Phase II Trial', 'acronym': 'TIDALS'}, 'statusModule': {'statusVerifiedDate': '2023-06', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-03-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-10-04', 'studyFirstSubmitQcDate': '2021-10-24', 'studyFirstPostDateStruct': {'date': '2021-11-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-06-01', 'lastUpdatePostDateStruct': {'date': '2023-06-02', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Annemarie Hübers', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'University Hospital, Geneva'}, 'leadSponsor': {'name': 'University Hospital, Geneva', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Lausanne Hospitals', 'class': 'OTHER'}, {'name': 'University of Zurich', 'class': 'OTHER'}, {'name': 'University of Bern', 'class': 'OTHER'}, {'name': 'Cantonal Hospital of St. Gallen', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of only three to five years. The disease is characterized by pathological accumulations of a protein called TDP-43, which can be found large cortical and sub-cortical areas of post-mortem ALS brains.\\n\\nNo causal treatment for this condition is known to date, and there is a large unmet need to develop new strategies in order to halt or slow down its progression.\\n\\nThe aim of this study is to test the safety and tolerability of Tideglusib, a treatment that is already in clinical trials for other neuromuscular conditions, in patients with ALS. It is assumed that this drug may have a significant therapeutic benefit in this population due to his mode of action: In the ALS mouse model, Tideglusib decreases significantly the amount of accumulated TDP-43 proteins within the cells.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Double-blind', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 98, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Tideglusib', 'type': 'EXPERIMENTAL', 'description': 'Patients receive 1000 mg Tideglusib once daily per os', 'interventionNames': ['Drug: Tideglusib']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Patients receive placebo matching Tideglusib 100 mg once daily per os', 'interventionNames': ['Drug: Tideglusib']}], 'interventions': [{'type': 'DRUG', 'name': 'Tideglusib', 'description': '1000 mg/day per os', 'armGroupLabels': ['Placebo', 'Tideglusib']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Increase in Alanine Aminotransferase', 'description': 'Increase in Alanine Aminotransferase \\\\< 3x of Upper Limit of Normal', 'timeFrame': '14 weeks'}], 'secondaryOutcomes': [{'measure': 'Most common side effect', 'description': 'Occurence of diarrhea in less then 18 % of patients', 'timeFrame': '14 weeks'}], 'otherOutcomes': [{'measure': 'Exploratory outcome: clinical efficacy', 'description': 'Difference of decline in points on the Revised ALS Functional Rating Scale between the two study arms', 'timeFrame': '14 weeks'}, {'measure': 'Exploratory outcome: vital capacity', 'description': 'slow vital capacity in %', 'timeFrame': '14 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Possible, probable (clinically or laboratory supported) or definite ALS according to the revised version of the El Escorial criteria\\n* Disease duration \\\\< 18 months\\n* Vital capacity of more than 60% of normal (defined as slow vital capacity, best of three measurements)\\n* Age more than 18 years\\n* On a stable dose of riluzole for at least four weeks or not taking riluzole\\n* On a stable dose of edaravone for at least four weeks or not taking edaravone\\n* Capable of thoroughly understanding all information given and giving full informed consent according to GCP\\n\\nExclusion Criteria:\\n\\n* Previous participation in another clinical study within the preceding 12 weeks\\n* Proven SOD1- or FUS - mutation\\n* Tracheostomy or assisted ventilation of any type during the preceding three months\\n* Pregnancy or breast-feeding females\\n* Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS\\n* Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment\\n* Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms\\n* Alcoholism\\n* Cardiovascular disorder/arrhythmia\\n* Impaired kidney function, defined as creatinine levels of 2.5 x upper limit of normal (ULN)\\n* Impaired liver function, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) of 3 x ULN\\n* Liable to be not cooperative or comply with trial requirements as assessed by the investigator, or unable to be reached in the case of emergency', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Annemarie Hübers', 'role': 'CONTACT', 'phone': '0795531171', 'email': 'annemarie.hubers@hcuge.ch'}], 'overallOfficials': [{'name': 'Annemarie Hübers', 'affiliation': 'University Hospital, Geneva', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University Hospital Bern', 'city': 'Bern', 'country': 'Switzerland', 'contacts': [{'name': 'Olivier Scheidegger', 'role': 'CONTACT'}], 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'facility': 'University Hospital Geneva', 'city': 'Genève', 'zip': '1205', 'country': 'Switzerland', 'contacts': [{'name': 'Annemarie Hübers', 'role': 'CONTACT', 'phone': '0795531171', 'email': 'annemarie.hubers@hcuge.ch'}], 'geoPoint': {'lat': 46.20222, 'lon': 6.14569}}, {'facility': 'University Hospital Lausanne', 'city': 'Lausanne', 'country': 'Switzerland', 'contacts': [{'name': 'David Benninger', 'role': 'CONTACT'}], 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'facility': 'Kantonsspital St. Gallen', 'city': 'Saint-Gall', 'country': 'Switzerland', 'contacts': [{'name': 'Markus Weber', 'role': 'CONTACT'}], 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'facility': 'University Hospital Zurich', 'city': 'Zürich', 'country': 'Switzerland', 'contacts': [{'name': 'Hans Jung', 'role': 'CONTACT'}], 'geoPoint': {'lat': 47.36667, 'lon': 8.54999}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00349622', 'orgStudyIdInfo': {'id': 'U01NS049640-02', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/U01NS049640-02'}, 'secondaryIdInfos': [{'id': 'NINDS', 'type': 'OTHER', 'domain': 'NINDS'}, {'id': 'U01NS049640-02', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/U01NS049640-02'}, {'id': 'NINDS CRC', 'type': 'OTHER', 'domain': 'NINDS Clinical Research Collaboration'}], 'organization': {'fullName': 'Massachusetts General Hospital', 'class': 'OTHER'}, 'briefTitle': 'Clinical Trial Ceftriaxone in Subjects With ALS', 'officialTitle': 'Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)'}, 'statusModule': {'statusVerifiedDate': '2014-04', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2006-07'}, 'primaryCompletionDateStruct': {'date': '2012-11', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2012-11', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-07-05', 'studyFirstSubmitQcDate': '2006-07-05', 'studyFirstPostDateStruct': {'date': '2006-07-07', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2013-10-23', 'resultsFirstSubmitQcDate': '2014-02-14', 'resultsFirstPostDateStruct': {'date': '2014-04-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2014-04-01', 'lastUpdatePostDateStruct': {'date': '2014-04-21', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Merit E. Cudkowicz, MD', 'investigatorTitle': 'Professor of Neurology', 'investigatorAffiliation': 'Massachusetts General Hospital'}, 'leadSponsor': {'name': 'Massachusetts General Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).', 'detailedDescription': 'It is known that nerve cells called motor neurons die in the brains and spinal cords of people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is unknown. Researchers think that increased levels of a chemical called \"glutamate\" may be related to the cell death. For this reason researchers want to study drugs that decrease glutamate levels near nerves. Ceftriaxone-a semi-synthetic, third generation cephalosporin antibiotic-may increase the level of a protein that decreases glutamate levels near nerves. Studies of ceftriaxone in the laboratory suggest that it may protect motor neurons from injury.\\n\\nCeftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS.\\n\\nA total of 600 eligible people with ALS will be enrolled in this multi-center research study. Participants will be randomly assigned to receive treatment with ceftriaxone (2/3 of participants) or placebo (1/3 of participants) for at least 12 months.\\n\\nThe study consists of three stages. The first stage, which has completed enrollment, will look at whether ceftriaxone enters the cerebrospinal fluid (the fluid that surrounds the spinal cord, also called CSF) in amounts that are high enough to be of possible benefit. The second stage, which has also completed enrollment, will look at the safety and side effects of the study drug when taken daily for at least 20 weeks. The study is currently enrolling subjects for the third stage, which began in Spring 2009, and will determine whether the study drug prolongs survival and slows decline in function due to ALS.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis', 'ALS'], 'keywords': ['amyotrophic lateral sclerosis', 'ALS', 'ceftriaxone', 'cephalosporin antibiotic', 'motor neurons']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 513, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Ceftriaxone', 'type': 'ACTIVE_COMPARATOR', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.', 'interventionNames': ['Drug: ceftriaxone']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.', 'interventionNames': ['Other: placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'ceftriaxone', 'description': 'Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years.', 'armGroupLabels': ['Ceftriaxone']}, {'type': 'OTHER', 'name': 'placebo', 'description': 'an inactive substance', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Survival', 'description': 'Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV).', 'timeFrame': \"From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)\"}, {'measure': 'Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year', 'description': \"Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.\\n\\nThis outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year.\", 'timeFrame': 'Every 8 weeks for one year'}], 'secondaryOutcomes': [{'measure': 'Change in % Vital Capacity From Screening to One Year', 'description': 'Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.', 'timeFrame': 'Every 12 weeks for one Year'}, {'measure': 'Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year', 'description': \"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.\\n\\nHHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.\", 'timeFrame': 'Every 12 weeks for one Year'}, {'measure': 'Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year', 'description': 'The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.', 'timeFrame': 'Every 12 weeks for one Year'}, {'measure': 'Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year', 'description': \"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.\\n\\nHHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.\", 'timeFrame': 'Every 12 weeks for one Year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Participants will be people with ALS, at least 18 years of age.\\n* Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration.\\n* Participants should live within a reasonable distance of the study site, due to frequent study visits.\\n\\nExclusion Criteria:\\n\\n* Participants cannot be taking any other experimental medications for ALS, or have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz).', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Merit Cudkowicz, MD, MSc.', 'affiliation': 'Associate Professor of Neurology, Harvard Medical School, Massachusetts General Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Phoenix Neurological Associates', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85018', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'University of California, Davis', 'city': 'Davis', 'state': 'California', 'zip': '95819', 'country': 'United States', 'geoPoint': {'lat': 38.54491, 'lon': -121.74052}}, {'facility': 'University of California, San Francisco- Fresno', 'city': 'Fresno', 'state': 'California', 'zip': '93701', 'country': 'United States', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'facility': 'Loma Linda University School of Medicine (CA)', 'city': 'Loma Linda', 'state': 'California', 'zip': '92354', 'country': 'United States', 'geoPoint': {'lat': 34.04835, 'lon': -117.26115}}, {'facility': 'Cedars-Sinai Medical Center', 'city': 'Los Angeles', 'state': 'California', 'zip': '90048', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'University of California, Los Angeles', 'city': 'Los Angeles', 'state': 'California', 'zip': '90095', 'country': 'United States', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'University of California, Irvine - MDA ALS Neuromuscular Center', 'city': 'Orange', 'state': 'California', 'zip': '92868', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}, {'facility': 'California Pacific Medical Center', 'city': 'San Francisco', 'state': 'California', 'zip': '94115', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'University of California, San Francisco', 'city': 'San Francisco', 'state': 'California', 'zip': '94117', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'University of Colorado Health Sciences Center', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Hospital for Special Care', 'city': 'New Britain', 'state': 'Connecticut', 'zip': '06053', 'country': 'United States', 'geoPoint': {'lat': 41.66121, 'lon': -72.77954}}, {'facility': 'George Washington University', 'city': 'Washington', 'state': 'District of Columbia', 'zip': '20037', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'Mayo Clinic Jacksonville', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32224', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'University of Miami School of Medicine', 'city': 'Miami', 'state': 'Florida', 'zip': '33136', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'ALS Center at Emory University', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30322', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Medical College of Georgia', 'city': 'Augusta', 'state': 'Georgia', 'zip': '30912', 'country': 'United States', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'facility': 'Northwestern University Medical School', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60611', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Indiana University (Regenstrief Health Center)', 'city': 'Indianapolis', 'state': 'Indiana', 'zip': '46202', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'facility': 'University of Kansas Medical Center', 'city': 'Kansas City', 'state': 'Kansas', 'zip': '66161', 'country': 'United States', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'facility': 'University of Kentucky Medical Center', 'city': 'Lexington', 'state': 'Kentucky', 'zip': '40536', 'country': 'United States', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'facility': 'Massachusetts General Hospital', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Lahey Clinic', 'city': 'Burlington', 'state': 'Massachusetts', 'zip': '01805', 'country': 'United States', 'geoPoint': {'lat': 42.50482, 'lon': -71.19561}}, {'facility': 'Henry Ford Health System', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48202', 'country': 'United States', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': \"Saint Mary's Healthcare\", 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49503', 'country': 'United States', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Hennepin County Medical Center (Berman Center)', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55404', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}, {'facility': 'St. Louis University', 'city': 'St. Louis', 'state': 'Missouri', 'zip': '63104', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'Washington University', 'city': 'St. Louis', 'state': 'Missouri', 'zip': '63110', 'country': 'United States', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'facility': 'Bryan LGH Medical Center (University of Nebraska)', 'city': 'Lincoln', 'state': 'Nebraska', 'zip': '68506', 'country': 'United States', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'facility': 'UMDNJ- Robert Wood Johnson School of Medicine', 'city': 'New Brunswick', 'state': 'New Jersey', 'zip': '08901', 'country': 'United States', 'geoPoint': {'lat': 40.48622, 'lon': -74.45182}}, {'facility': 'Albany Medical Center', 'city': 'Albany', 'state': 'New York', 'zip': '12208', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'facility': 'Beth Israel Medical Center (NY)', 'city': 'New York', 'state': 'New York', 'zip': '10003', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Cornell Medical Center', 'city': 'New York', 'state': 'New York', 'zip': '10021', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Columbia University', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'SUNY Upstate Medical University', 'city': 'Syracuse', 'state': 'New York', 'zip': '13210', 'country': 'United States', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'facility': 'Carolinas Medical Center', 'city': 'Charlotte', 'state': 'North Carolina', 'zip': '28203', 'country': 'United States', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'facility': 'Wake Forest University School of Medicine', 'city': 'Winston-Salem', 'state': 'North Carolina', 'zip': '27157', 'country': 'United States', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'facility': 'The Cleveland Clinic Foundation', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44195', 'country': 'United States', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Ohio State University', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43210', 'country': 'United States', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Oregon Clinic (Providence Clinic)', 'city': 'Portland', 'state': 'Oregon', 'zip': '97213', 'country': 'United States', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'facility': 'Pennsylvania State University, Hershey Medical Center', 'city': 'Hershey', 'state': 'Pennsylvania', 'zip': '17033', 'country': 'United States', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'facility': 'Drexel University College of Medicine (Hahnemann Campus)', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19107', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'University of Pennsylvania', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19107', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Allegheny Hospital', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15212', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'University of Pittsburgh', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15213', 'country': 'United States', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Medical University of South Carolina', 'city': 'Charleston', 'state': 'South Carolina', 'zip': '29403', 'country': 'United States', 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}}, {'facility': 'Vanderbilt University', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37232', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Texas Neurology', 'city': 'Dallas', 'state': 'Texas', 'zip': '75214', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Methodist Neurological Institute', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'University of Utah Health Sciences Center', 'city': 'Salt Lake City', 'state': 'Utah', 'zip': '84132', 'country': 'United States', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'facility': 'University of Virginia', 'city': 'Charlottesville', 'state': 'Virginia', 'zip': '22908', 'country': 'United States', 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'facility': 'University of Calgary', 'city': 'Calgary', 'state': 'Alberta', 'zip': 'T2N 4Z6', 'country': 'Canada', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'facility': 'Univeristy of Alberta ALS Clinic', 'city': 'Edmonton', 'state': 'Alberta', 'zip': 'T6G 2B7', 'country': 'Canada', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'facility': 'Dalhousie University', 'city': 'Halifax', 'state': 'Nova Scotia', 'country': 'Canada', 'geoPoint': {'lat': 44.64533, 'lon': -63.57239}}, {'facility': 'London Health Sciences Center, University Campus', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'facility': 'University of Toronto', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': \"CHUM (Centre Hospitalier de l'Université de Montréal), Notre-Dame Hospital\", 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Montreal Neurological Institute (McGill University)', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Laval University', 'city': 'Quebec City', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}]}, 'referencesModule': {'references': [{'pmid': '28864675', 'type': 'DERIVED', 'citation': 'McDonnell E, Schoenfeld D, Paganoni S, Atassi N. Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. Neurology. 2017 Oct 3;89(14):1483-1489. doi: 10.1212/WNL.0000000000004534. Epub 2017 Sep 1.'}, {'pmid': '25297012', 'type': 'DERIVED', 'citation': 'Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, Hayden D, Shui A, Brooks B, Conwit R, Felsenstein D, Greenblatt DJ, Keroack M, Kissel JT, Miller R, Rosenfeld J, Rothstein JD, Simpson E, Tolkoff-Rubin N, Zinman L, Shefner JM; Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 Nov;13(11):1083-1091. doi: 10.1016/S1474-4422(14)70222-4. Epub 2014 Oct 5.'}, {'pmid': '23613806', 'type': 'DERIVED', 'citation': 'Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, Caress JB, Katz J, Simpson E, Rosenfeld J, Pascuzzi R, Glass J, Rezania K, Rothstein JD, Greenblatt DJ, Cudkowicz ME; Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One. 2013 Apr 17;8(4):e61177. doi: 10.1371/journal.pone.0061177. Print 2013.'}], 'seeAlsoLinks': [{'label': 'Northeast ALS Consortium website', 'url': 'http://www.alsconsortium.org'}]}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Participants were randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants received ceftriaxone and one third received placebo. This is a blinded study, so neither participants nor study staff knew which treatment a participant is receiving.', 'recruitmentDetails': 'Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Subjects with ALS were enrolled in 58 institutions across in the US and Canada.', 'groups': [{'id': 'FG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'FG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '340'}, {'groupId': 'FG001', 'numSubjects': '173'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '162'}, {'groupId': 'FG001', 'numSubjects': '77'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '178'}, {'groupId': 'FG001', 'numSubjects': '96'}]}], 'dropWithdraws': [{'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '168'}, {'groupId': 'FG001', 'numSubjects': '86'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '9'}]}]}]}, 'baselineCharacteristicsModule': {'groups': [{'id': 'BG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'BG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '340'}, {'groupId': 'BG001', 'value': '173'}, {'groupId': 'BG002', 'value': '513'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'title': 'Age at Screening', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '55.6', 'spread': '10.4'}, {'groupId': 'BG001', 'value': '54.8', 'spread': '10.3'}, {'groupId': 'BG002', 'value': '55.4', 'spread': '10.4'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '131'}, {'groupId': 'BG001', 'value': '72'}, {'groupId': 'BG002', 'value': '203'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '209'}, {'groupId': 'BG001', 'value': '101'}, {'groupId': 'BG002', 'value': '310'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '17'}, {'groupId': 'BG001', 'value': '6'}, {'groupId': 'BG002', 'value': '23'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '320'}, {'groupId': 'BG001', 'value': '165'}, {'groupId': 'BG002', 'value': '485'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '3'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '5'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '6'}, {'groupId': 'BG001', 'value': '5'}, {'groupId': 'BG002', 'value': '11'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '1'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '3'}, {'groupId': 'BG002', 'value': '11'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '320'}, {'groupId': 'BG001', 'value': '163'}, {'groupId': 'BG002', 'value': '483'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '2'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '2'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '2'}, {'groupId': 'BG002', 'value': '3'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '293'}, {'groupId': 'BG001', 'value': '151'}, {'groupId': 'BG002', 'value': '444'}]}]}, {'title': 'Canada', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '47'}, {'groupId': 'BG001', 'value': '22'}, {'groupId': 'BG002', 'value': '69'}]}]}]}, {'title': 'ALS Family History', 'description': 'Subjects were asked at screening whether or not they have a familial history of ALS.', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Familial History of ALS', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '26'}, {'groupId': 'BG001', 'value': '8'}, {'groupId': 'BG002', 'value': '34'}]}]}, {'title': 'No Known Familial History of ALS', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '307'}, {'groupId': 'BG001', 'value': '161'}, {'groupId': 'BG002', 'value': '468'}]}]}, {'title': 'Unknown', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '7'}, {'groupId': 'BG001', 'value': '4'}, {'groupId': 'BG002', 'value': '11'}]}]}]}, {'title': 'Site of Onset', 'description': 'Indicates region of first symptoms', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Limb', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '257'}, {'groupId': 'BG001', 'value': '137'}, {'groupId': 'BG002', 'value': '394'}]}]}, {'title': 'Bulbar', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '75'}, {'groupId': 'BG001', 'value': '35'}, {'groupId': 'BG002', 'value': '110'}]}]}, {'title': 'Both', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '8'}, {'groupId': 'BG001', 'value': '1'}, {'groupId': 'BG002', 'value': '9'}]}]}]}, {'title': 'Riluzole Use', 'description': 'At the screening visit, subjects were asked whether or not they were taking a continuous dose of riluzole.', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'On Riluzole', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '249'}, {'groupId': 'BG001', 'value': '128'}, {'groupId': 'BG002', 'value': '377'}]}]}, {'title': 'Not on Riluzole', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '91'}, {'groupId': 'BG001', 'value': '45'}, {'groupId': 'BG002', 'value': '136'}]}]}]}, {'title': 'Vital Capacity Percent Predicted', 'description': 'The vital capacity (lung capacity) for each subject was measured at screening.', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'percent predicted based on age and heigh', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '87.9', 'spread': '16.6'}, {'groupId': 'BG001', 'value': '91.1', 'spread': '18.4'}, {'groupId': 'BG002', 'value': '89.0', 'spread': '17.3'}]}]}]}, {'title': 'Time to Screening', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'title': 'Years from Symptom Onset to Screening', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '1.49', 'spread': '0.68'}, {'groupId': 'BG001', 'value': '1.50', 'spread': '0.67'}, {'groupId': 'BG002', 'value': '1.49', 'spread': '0.68'}]}]}, {'title': 'Years from Diagnosis to Screening', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '0.56', 'spread': '0.49'}, {'groupId': 'BG001', 'value': '0.58', 'spread': '0.49'}, {'groupId': 'BG002', 'value': '0.57', 'spread': '0.49'}]}]}, {'title': 'Years from Symptom Onset to Diagnosis', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '0.93', 'spread': '0.55'}, {'groupId': 'BG001', 'value': '0.92', 'spread': '0.58'}, {'groupId': 'BG002', 'value': '0.92', 'spread': '0.56'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Survival', 'description': 'Survival is presented as median day of survival for each group. Survival is defined as time to death, tracheostomy or the initiation of permanent assisted ventilation (PAV).', 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'days', 'timeFrame': \"From date of randomization until date of death, tracheostomy, or the initiation of permanent assisted ventilation (PAV). This was assessed at time of each participant's drug discontinuation and every 2 months thereafter for the life of the study (6 yrs)\", 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '664', 'lowerLimit': '614', 'upperLimit': '794'}, {'groupId': 'OG001', 'value': '581', 'lowerLimit': '521', 'upperLimit': '672'}]}]}]}, {'type': 'PRIMARY', 'title': 'Change From Baseline in ALS Functional Rating Scale, Revised (ALSFRS-R) at One Year', 'description': \"Amyotrophic Lateral Sclerosis Functional Rating Scale, Revised (ALSFRS-R) is a quickly administered (five minute) ordinal rating scale used to determine patients' assessment of their capability and independence in 12 functional activities/questions. The 12 functional activities/questions are rated on a scale of 0 to 4 for a total scoring range of 0-48, with 48 representing optimal function. All 12 activities are relevant in ALS.\\n\\nThis outcome measure calculation is based on measurements every 8 weeks from the Baseline Visit up until one year.\", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale per 8 weeks', 'timeFrame': 'Every 8 weeks for one year', 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.1311', 'spread': '0.04395'}, {'groupId': 'OG001', 'value': '-1.2208', 'spread': '0.06177'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change in % Vital Capacity From Screening to One Year', 'description': 'Vital Capacity is measured as the percent predicted per subject based on age, gender, and height, and is performed as a Slow Vital Capacity.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percent change in VC per 12 weeks', 'timeFrame': 'Every 12 weeks for one Year', 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.772', 'spread': '0.1417'}, {'groupId': 'OG001', 'value': '-3.0826', 'spread': '0.1970'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Evaluation of Multiple Upper Extremity Muscles Using Hand Held Dynamometry at One Year', 'description': \"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.\\n\\nHHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.\", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Percent change per 12 weeks', 'timeFrame': 'Every 12 weeks for one Year', 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-5.2735', 'spread': '0.2178'}, {'groupId': 'OG001', 'value': '-5.5526', 'spread': '0.3040'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in the ALS-Specific Quality of Life Scale (ALSQOL) at One Year', 'description': 'The ALS-Specific Quality of Life Scale (ALSQOL). was developed, tested, and validated in subjects with ALS, and is not a health-related quality of life scale. The scale consists of 59 questions that ask about severity of the symptoms of ALS, mood and affect, intimacy, and social issues. Each question for the ALSQOL is scored from 0-10. With 59 questions, total score ranges from 0-590 with scores simply added, with 590 representing highest quality of life. However since 10 is maximally weighted towards negative values on some questions and positive values on others, the following questions must have results transposed (Simply reverse the scale, for instance 10=0 and 0=10) prior to analysis: 1-10, 11, 16, 19, 24, 26, 28, 32, 35, 36, 38, and 41. Optional items are 50, 53, 56, and 59. These questions are not included on any scale or in any quantitative analyses.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale per 12 weeks', 'timeFrame': 'Every 12 weeks for one Year', 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.5084', 'spread': '0.3297'}, {'groupId': 'OG001', 'value': '-3.4401', 'spread': '0.4629'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Evaluation of Multiple Lower Extremity Muscles Using Hand Held Dynamometry at One Year', 'description': \"Hand-held Dynamometry (HHD) is used to evaluate muscle strength. Six proximal muscle groups were examined bilaterally in both upper and lower extremities (shoulder flexion, elbow flexion, elbow extension, hip flexion, knee flexion, and knee extension). In addition, wrist extension, first dorsal interosseous contraction and ankle dorsiflexion were measured bilaterally.\\n\\nHHD analysis was performed using Percent Change from Baseline. Each subject's baseline strength value for each muscle group is considered 100%. During successive visits strength for each muscle group was measured using HHD and was calculated as a percentage of the initial baseline value recorded. Upper extremity and lower extremity values were calculated as the sum of all tests for that extremity to create one megascore for upper and one megascore for lower extremity muscles.\\n\\nThis outcome measure calculation is based on measurements every 12 weeks from the Baseline Visit up until one year.\", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'Percent change per 12 weeks', 'timeFrame': 'Every 12 weeks for one Year', 'groups': [{'id': 'OG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.'}, {'id': 'OG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '340'}, {'groupId': 'OG001', 'value': '173'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-4.1530', 'spread': '0.2591'}, {'groupId': 'OG001', 'value': '-4.4807', 'spread': '0.3625'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation. The total amount of time per subject varies by length of subject participation.', 'description': 'Adverse Events were systematically assessed by study investigators at each study visit from the screening visit until 30 days after permanent study drug discontinuation.', 'eventGroups': [{'id': 'EG000', 'title': 'Ceftriaxone', 'description': 'Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nCeftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day.', 'seriousNumAffected': 276, 'seriousNumAtRisk': 340, 'otherNumAffected': 331, 'otherNumAtRisk': 340}, {'id': 'EG001', 'title': 'Placebo', 'description': 'One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.\\n\\nPediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day.', 'seriousNumAffected': 125, 'seriousNumAtRisk': 173, 'otherNumAffected': 153, 'otherNumAtRisk': 173}], 'seriousEvents': [{'term': 'Dyspnea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 79, 'numAffected': 74, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 35, 'numAffected': 34, 'numAtRisk': 173}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 30, 'numAffected': 28, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Infections with unknown ANC: Lung (pneumonia)', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 17, 'numAffected': 13, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Thrombosis/thrombus/embolism', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 20, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 173}]}, {'term': 'Line Infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Line Infection\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 9, 'numAtRisk': 173}]}, {'term': 'Renal/Genitourinary - Other', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 10, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'PEG Placement (outpatient)', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': 'PEG (Percutaneous Endoscopic Gastrostomy) Placement was added as an adverse event term during STAGES 1 and 2 of this study. PEG tube placements are common for people with ALS. In STAGE 3 of the study, these events were coded as Dysphagia.', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 173}]}, {'term': 'Aspiration', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Death not associated with CTCAE Term: Disease Progression NOS', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 173}]}, {'term': 'Cardiac ischemia/infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 8, 'numAffected': 6, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Dysphagia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Infection with normal ANC or grade 1 or 2 neutrophils: Lung (pneumonia)', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Catheter Exit Site Infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Catheter Exit Site Infection\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Cholecystitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Allergic reaction/hypersensitivity (including drug fever)', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Death not associated with CTCAE term: Death NOS', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Fever (in the absense of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Infection with normal ANC or grade 1 or 2 neutrophils: Blood', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Infections with unknown ANC: Blood', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Pain: Abdomen NOS', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Pulmonary - Other', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Colitis infectious (Clostridium difficile)', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Diarrhea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Gastrointestinal - Other', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Urinary tract NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 173}]}, {'term': 'Joint-function', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Blood/Bone Marrow - Other', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'CNS cerebrovascular ischemia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Death not associated with CTCAE Term: Sudden Death', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Dehydration', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hematoma', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hypoxia', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Line break/tear', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Line break/tear\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Line Displacement', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Line Displacement\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Mood alteration: Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Musculoskeletal - Other', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Neurology - Other', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Obstruction/stenosis of airway: Larynx', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Pneumonitis/pulmonary infiltrates', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Pneumothorax', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Somnolence/depressed level of consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Atelectasis', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Biliary Sludge', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Cardiac/Arrhythmia Other', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Cognitive disturbance', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Colitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Confusion', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Dermatology/Skin - Other', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'FEV (1)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Febrile neutropenia (fever of unknown origin w/out clinically/microbiologically documented infection', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Gastritis (including bile reflux gastritis)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Heartburn/Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Hemmorhage, CNS', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Hemmorhage, GI: Lower GI NOS', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Hemmorhage, GI: Stomach', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hemmorhage, pulmonary/Upper Respiratory: Stoma', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hemorrhage/bleeding associated with surgery, intraoperative or postoperative', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hepatobiliary - Other', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Hypotension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia: Lung', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Infection - Other', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Infection with normal ANC or grade 1 or 2 neutrophils: Bronchus', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Infection with normal ANC or grade 1 or 2 neutrophils: Vagina', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Abdomen NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Catheter-related', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Foreign body (e.g. graft, implant, prosthesis, stent)', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Soft tissue NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Leak (including anastomotic), GI: Stomach', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Left ventricular diastolic dysfunction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Line Thrombosis', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Line Thrombosis\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Metabolic/Laboratory - Other', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Mood alteration: Agitation', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Mood alteration: Anxiety', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Neutrophils/granulocytes (ANC/AGC)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Obstruction, GI: Ileum', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Obstruction, GI: Stomach', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Obstruction/stenosis of airway: Trachea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Pain: chest wall', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Pain: Chest/thorax NOS', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Pain: Head/headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Pain: Stomach', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Potassium, serum-low (hypokalemia)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Renal failure', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Sexual/Reproductive Function - Other', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Stricture/stenosis (including anastomotic), GU: Ureter', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Supraventricular and nodal arrhythmias: Sinus bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Thrombosis/embolism (vascular access-related)', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Urinary retention (including nerogenic bladder)', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Ventricular arrhythmia: Ventricular tachycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}, {'term': 'Weight loss', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 173}]}, {'term': 'Pancreatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 173}]}], 'otherEvents': [{'term': 'Diarrhea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 220, 'numAffected': 152, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 51, 'numAffected': 41, 'numAtRisk': 173}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 193, 'numAffected': 158, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 173}]}, {'term': 'Dyspnea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 38, 'numAffected': 32, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 24, 'numAtRisk': 173}]}, {'term': 'Neurology - Other', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 183, 'numAffected': 97, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 92, 'numAffected': 52, 'numAtRisk': 173}]}, {'term': 'Catheter Exit Site Reaction', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0) suppl.', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Catheter Exit Site Reaction\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 143, 'numAffected': 98, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 69, 'numAffected': 45, 'numAtRisk': 173}]}, {'term': 'Rash/desquamation', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 122, 'numAffected': 92, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 36, 'numAffected': 29, 'numAtRisk': 173}]}, {'term': 'Biliary Sludge', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 110, 'numAffected': 100, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 76, 'numAffected': 66, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 34, 'numAffected': 30, 'numAtRisk': 173}]}, {'term': 'Pain: Abdomen NOS', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 114, 'numAffected': 75, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 16, 'numAtRisk': 173}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 115, 'numAffected': 64, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 39, 'numAffected': 28, 'numAtRisk': 173}]}, {'term': 'Pain: head/headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 79, 'numAffected': 53, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 37, 'numAffected': 32, 'numAtRisk': 173}]}, {'term': 'Dermatology/Skin - Other', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 78, 'numAffected': 57, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 21, 'numAtRisk': 173}]}, {'term': 'Edema: Limb', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 68, 'numAffected': 54, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 22, 'numAtRisk': 173}]}, {'term': 'Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-lower', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 61, 'numAffected': 46, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 30, 'numAffected': 26, 'numAtRisk': 173}]}, {'term': 'Pain: Back', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 59, 'numAffected': 53, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 17, 'numAtRisk': 173}]}, {'term': 'Pulmonary - Other', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 57, 'numAffected': 46, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 25, 'numAffected': 20, 'numAtRisk': 173}]}, {'term': 'Pain: Joint', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 62, 'numAffected': 47, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 24, 'numAffected': 19, 'numAtRisk': 173}]}, {'term': 'Fatigue (asthenia, lethargy, malaise)', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 44, 'numAffected': 41, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 24, 'numAtRisk': 173}]}, {'term': 'Musculoskeletal - Other', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 57, 'numAffected': 45, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 24, 'numAffected': 17, 'numAtRisk': 173}]}, {'term': 'Insomnia', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 42, 'numAffected': 40, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 173}]}, {'term': 'Dysphagia, (difficult swallowing)', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 38, 'numAffected': 35, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 17, 'numAtRisk': 173}]}, {'term': 'Infection - Other', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 64, 'numAffected': 42, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 18, 'numAffected': 15, 'numAtRisk': 173}]}, {'term': 'Muscle weakness, generalized or specific area (not due to neuropathy): Extremity-upper', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 48, 'numAffected': 39, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 22, 'numAffected': 19, 'numAtRisk': 173}]}, {'term': 'Renal/Genitourinary - Other', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 57, 'numAffected': 37, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 20, 'numAffected': 13, 'numAtRisk': 173}]}, {'term': 'Mood alteration: Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 33, 'numAffected': 33, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 21, 'numAffected': 21, 'numAtRisk': 173}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 48, 'numAffected': 41, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Gastrointestinal - Other', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 41, 'numAffected': 36, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Mood alteration: Anxiety', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 38, 'numAffected': 34, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 173}]}, {'term': 'Pain: Neck', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 37, 'numAffected': 34, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 15, 'numAtRisk': 173}]}, {'term': 'Pain: Extremity-limb', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 53, 'numAffected': 38, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 10, 'numAtRisk': 173}]}, {'term': 'Pruritis/itching', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 41, 'numAffected': 33, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 173}]}, {'term': 'Drooling', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 30, 'numAffected': 30, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 16, 'numAtRisk': 173}]}, {'term': 'Infection with normal ANC or grade 1 or 2 neutrophils: Urinary Tract NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 29, 'numAffected': 25, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 24, 'numAffected': 17, 'numAtRisk': 173}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 32, 'numAffected': 25, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 18, 'numAffected': 15, 'numAtRisk': 173}]}, {'term': 'Fever (absence of neutropenia, where neutropenia is AGC <1.0x10e9/L)', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 28, 'numAffected': 27, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'ALT SGPT (serum glutamic pyruvic transaminase)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 42, 'numAffected': 32, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 173}]}, {'term': 'Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 23, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 14, 'numAtRisk': 173}]}, {'term': 'Pain: chest wall', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 29, 'numAffected': 25, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 17, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Heartburn/Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 24, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Voice changes/dysarthria (e.g., hoarseness, loss or alteration of voice, laryngitis)', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 27, 'numAffected': 25, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 173}]}, {'term': 'Muscle weakness, generalized of specific area (not due to neuropathy): Whole body/generalized', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 29, 'numAffected': 27, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 8, 'numAtRisk': 173}]}, {'term': 'Bruising (in absence of grade 3 or 4 thrombocytopenia)', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 44, 'numAffected': 24, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 10, 'numAtRisk': 173}]}, {'term': 'Fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 29, 'numAffected': 24, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 10, 'numAtRisk': 173}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 33, 'numAffected': 24, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 10, 'numAtRisk': 173}]}, {'term': 'Neutrophils/granulocytes (ANC/AGC)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 41, 'numAffected': 30, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 173}]}, {'term': 'Metabolic/Laboratory', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 18, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 20, 'numAffected': 13, 'numAtRisk': 173}]}, {'term': 'Urinary frquency/urgency', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 21, 'numAffected': 20, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 11, 'numAtRisk': 173}]}, {'term': 'Line break/tear', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'notes': '\"Line break/tear\" was added to the trial database as an adverse event potentially related to the central venous catheter that all subjects received as part of the study.', 'stats': [{'groupId': 'EG000', 'numEvents': 21, 'numAffected': 19, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 11, 'numAtRisk': 173}]}, {'term': 'Pain - Other', 'organSystem': 'General disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 18, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 12, 'numAtRisk': 173}]}, {'term': 'Infection with unknown ANC: Upper airway NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 34, 'numAffected': 20, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 173}]}, {'term': 'Infection with unkown ANC: Urinary tract NOS', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 18, 'numAffected': 17, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 11, 'numAtRisk': 173}]}, {'term': 'AST SGOT (serum glutamic oxaloacetic transaminase)', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 27, 'numAffected': 23, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 173}]}, {'term': 'Allergic reaction/hypersensitivity (including drug fever)', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 19, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 173}]}, {'term': 'Weight loss', 'organSystem': 'Investigations', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 16, 'numAffected': 15, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 173}]}, {'term': 'Hepatobiliary - Other', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 20, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 173}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 16, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 173}]}, {'term': 'Lymphopenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'CTCAE (3.0)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 24, 'numAffected': 20, 'numAtRisk': 340}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 4, 'numAtRisk': 173}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'pointOfContact': {'title': 'Merit Cudkowicz', 'organization': 'MGH', 'email': 'mcudkowicz@partners.org', 'phone': '617-724-1873'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28', 'removedCountries': ['Puerto Rico']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000002443', 'term': 'Ceftriaxone'}], 'ancestors': [{'id': 'D000097911', 'term': 'Third Generation Cephalosporins'}, {'id': 'D000097902', 'term': 'Beta Lactam Antibiotics'}, {'id': 'D000000900', 'term': 'Anti-Bacterial Agents'}, {'id': 'D000000890', 'term': 'Anti-Infective Agents'}], 'browseLeaves': [{'id': 'M21860', 'name': 'Pharmaceutical Solutions', 'relevance': 'LOW'}, {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'}, {'id': 'M5760', 'name': 'Cephalosporins', 'relevance': 'LOW'}, {'id': 'M4224', 'name': 'Antibiotics, Antitubercular', 'relevance': 'LOW'}, {'id': 'M5693', 'name': 'Ceftriaxone', 'asFound': 'French', 'relevance': 'HIGH'}, {'id': 'M3453', 'name': 'Third Generation Cephalosporins', 'relevance': 'LOW'}, {'id': 'M10789', 'name': 'Lactams', 'relevance': 'LOW'}, {'id': 'M25772', 'name': 'beta-Lactams', 'relevance': 'LOW'}, {'id': 'M3444', 'name': 'Beta Lactam Antibiotics', 'relevance': 'LOW'}, {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'PhSol', 'name': 'Pharmaceutical Solutions'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00231140', 'orgStudyIdInfo': {'id': 'THL-ALS01'}, 'organization': {'fullName': 'Charite University, Berlin, Germany', 'class': 'OTHER'}, 'briefTitle': 'Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)', 'officialTitle': 'Randomized, Open, Parallel Group Study for the Evaluation of an Oral Dose of 100 mg Thalidomide and Subsequent Dose Escalation of 400 mg Thalidomide in Combination With Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)'}, 'statusModule': {'statusVerifiedDate': '2007-01', 'overallStatus': 'TERMINATED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2005-12'}, 'completionDateStruct': {'date': '2006-08'}, 'studyFirstSubmitDate': '2005-09-30', 'studyFirstSubmitQcDate': '2005-09-30', 'studyFirstPostDateStruct': {'date': '2005-10-04', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2007-01-18', 'lastUpdatePostDateStruct': {'date': '2007-01-19', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Charite University, Berlin, Germany', 'class': 'OTHER'}}, 'descriptionModule': {'briefSummary': 'Neuroinflammation has recently emerged as a significant contributor to motor neuron damage. ALS tissue is characterized by inflammatory changes that are observed in both sporadic and familial ALS and in the ALS superoxide dismutase 1 (SOD1) transgenic mouse model. They include an accumulation of large numbers of activated microglia and astrocytes.\\n\\nProinflammatory cytokines, such as tumor necrosis factor (TNF-), are robustly upregulated in ALS. The receptor for tumor necrosis factor- (TNF-R1) is elevated at late presymptomatic as well as symptomatic phases of disease. TNF acts as a principal driver for neuroinflammation in ALS, while several co-stimulating cytokines and chemokines act to potentiate the TNF effects \\\\[4-6\\\\].\\n\\nWe propose an investigational therapy of ALS with oral administration of thalidomide. The rationale for this study is based on the anti-inflammatory properties of thalidomide through the modulation of inflammatory cytokines such as TNF. The primary aim of the trial is to determine whether treatment with thalidomide is safe and well tolerated in conjunction with riluzole and whether patients with ALS can tolerate daily doses of up to 400 mg. The trial is designed as feasibility study in planning for a larger phase IIb/III trial of efficacy.', 'detailedDescription': 'Study drug will be provided as 50 mg tablets. Patients will be instructed to take 2 tablets orally once a day during the evening at least 60 minutes after a meal. Thalidomide will be administered starting at 100 mg (Group 1) for 6 weeks. Thereafter, the dose will be increased every week by 50mg until reaching the dose of 400 mg/day. This treatment is continued for 12 weeks. Thalidomide is administered in conjunction with the standard treatment of riluzole (100mg/day).'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis (ALS)'], 'keywords': ['ALS, motor neuron disease']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40}}, 'armsInterventionsModule': {'interventions': [{'type': 'DRUG', 'name': 'Thalidomide (drug)'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'to evaluate the long-term safety and tolerability of thalidomide'}, {'measure': 'to compare the total number of adverse events (AE), abnormal laboratory tests, and number of patients who completed the study between groups'}], 'secondaryOutcomes': [{'measure': 'to evaluate the clinical effect of two oral doses of the thalidomide on the rate of functional decline in ALS patients measured by the ALS Functional Rating Scale-revised (ALS-FRS-R) over a 24 week treatment period'}, {'measure': 'to investigate the effects of thalidomide on pulmonary function (forced vital capacity) over a 24 week treatment period'}, {'measure': 'to evaluate the sleep quality and somnolence using the Epworth Sleeping Scale: ESS ≥ 18'}, {'measure': 'to evaluate the frequency and severity of sensory neuropathy using the inflammatory neuropathy cause and treatment sensory sum score - ISS ≥ 4'}, {'measure': 'to evaluate the frequency of thrombotic events'}, {'measure': 'to determine the number of patients who require continuous non-invasive ventilation or invasive ventilation'}, {'measure': 'to determine the number of patients who require percutanous endoscopic gastrostomy (PEG)'}, {'measure': 'to evaluate the survival time or the time point until invasive ventilation is started'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* patients aged 25 and 80 years\\n* female patients who are either postmenopausal for at least 24 month or who are willing and able to practice the methods of contraception following the Pharmion-Risk Managment Program (PRMP)\\n* Male patients who are willing and able to practice the methods of contraception along with their female partners of childbearing potential following the PRMP\\n* Clinical diagnosis of probable and definite ALS\\n* Sporadic or familial ALS\\n* Onset of pareses for no more than 4 years\\n* Vital capacity equal to or more than 65% of the predicted value\\n* Treatment with riluzole 100mg/day\\n* Patients who are willing to give informed consent\\n\\nExclusion Criteria:\\n\\n* pregnancy or breast feeding\\n* female patients who are unwilling or unable to practice the methods of contraception following the Pharmion-Risk Managment Program (PRMP)\\n* Male patients who are willing and able to practice the methods of contraception along with their female partners of childbearing potential following the PRMP\\n* Patients unlikely to comply with the PRMP and other study requirements\\n* Patients with significant sensory abnormalities, dementia, uncompensated medical illnesses and psychiatric disorders\\n* Laboratory abnormalities consistent with clinically significant cardiovascular, respiratory, haematological, metabolic, hepatic and renal disease\\n* Infectious disease including HIV, hepatitis B and C\\n* monoclonal gammopathy of unknown significance (MGUS)\\n* History of substance abuse within the past year\\n* History of recurrent thrombosis\\n* Continuous non-invasive ventilation (ventilation-free interval equal to or less than 2 hours daily)\\n* Tracheotomy and invasive ventilation\\n* Treatment with investigational drug within 3 months prior to screening\\n* patients with clinically signifikant sensory polyneuropathy (inflammatory neuropathy cause and treatment sensory sum score - ISS ≥ 2)\\n* patients with sleep disorder (Epworth Sleeping Scale-ESS ≥ 10)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '25 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Thomas Meyer, MD', 'affiliation': 'Charité University Hospital, Berlin, Germany', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Charite University Hospital, Berlin, Germany', 'city': 'Berlin', 'zip': '13353', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}]}, 'referencesModule': {'references': [{'pmid': '18425621', 'type': 'DERIVED', 'citation': 'Meyer T, Maier A, Borisow N, Dullinger JS, Splettstosser G, Ohlraun S, Munch C, Linke P. Thalidomide causes sinus bradycardia in ALS. J Neurol. 2008 Apr;255(4):587-91. doi: 10.1007/s00415-008-0756-3. Epub 2008 Apr 21.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000013792', 'term': 'Thalidomide'}], 'ancestors': [{'id': 'D000007166', 'term': 'Immunosuppressive Agents'}, {'id': 'D000007155', 'term': 'Immunologic Factors'}, {'id': 'D000045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000007917', 'term': 'Leprostatic Agents'}, {'id': 'D000000900', 'term': 'Anti-Bacterial Agents'}, {'id': 'D000000890', 'term': 'Anti-Infective Agents'}, {'id': 'D000020533', 'term': 'Angiogenesis Inhibitors'}, {'id': 'D000043924', 'term': 'Angiogenesis Modulating Agents'}, {'id': 'D000006133', 'term': 'Growth Substances'}, {'id': 'D000006131', 'term': 'Growth Inhibitors'}, {'id': 'D000000970', 'term': 'Antineoplastic Agents'}], 'browseLeaves': [{'id': 'M16559', 'name': 'Thalidomide', 'asFound': 'Remote', 'relevance': 'HIGH'}, {'id': 'M21680', 'name': 'Riluzole', 'relevance': 'LOW'}, {'id': 'M10212', 'name': 'Immunosuppressive Agents', 'relevance': 'LOW'}, {'id': 'M10201', 'name': 'Immunologic Factors', 'relevance': 'LOW'}, {'id': 'M4222', 'name': 'Anti-Bacterial Agents', 'relevance': 'LOW'}, {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'}, {'id': 'M22318', 'name': 'Angiogenesis Inhibitors', 'relevance': 'LOW'}, {'id': 'M9231', 'name': 'Growth Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}, {'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AntiConv', 'name': 'Anticonvulsants'}, {'abbrev': 'NeuroAg', 'name': 'Neuroprotective Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03225144', 'orgStudyIdInfo': {'id': '170131'}, 'secondaryIdInfos': [{'id': '17-N-0131'}], 'organization': {'fullName': 'National Institutes of Health Clinical Center (CC)', 'class': 'NIH'}, 'briefTitle': 'Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia', 'officialTitle': 'Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia'}, 'statusModule': {'statusVerifiedDate': '2024-02-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-10-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-10-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2017-07-20', 'studyFirstSubmitQcDate': '2017-07-20', 'studyFirstPostDateStruct': {'date': '2017-07-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-08', 'lastUpdatePostDateStruct': {'date': '2024-02-09', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'class': 'NIH'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Background:\\n\\nNeurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells. Researchers want to understand whether these diseases have related causes or risk factors.\\n\\nObjective:\\n\\nTo test people with movement or thinking and memory problems to see if they are eligible for research studies.\\n\\nEligibility:\\n\\nPeople ages 18 and older with a neurodegenerative disorder associated with accumulation of TDP-43 or Tau proteins\\n\\nDesign:\\n\\nParticipants will have a screening visit. This may take place over 2-3 days. Tests include:\\n\\nMedical history\\n\\nPhysical exam\\n\\nQuestions about behavior and mood\\n\\nTests of memory, attention, concentration, and thinking\\n\\nMovement measurement. The speed at which participants can stand up from a chair, tap their finger and foot, and walk a short distance will be measured. Some movements will be videotaped. They will be videotaped while they speak and read a paragraph.\\n\\nBlood tests. This might include genetic testing.\\n\\nLung and breathing tests\\n\\nMRI. They will lie on a table that slides into a cylinder that takes pictures of the body. Some participants will get a dye through IV.\\n\\nElectromyography. A thin needle will be inserted into the muscles to measure electrical signals.\\n\\nNerve tests. Small electrodes on the skin record muscle and nerve activity.\\n\\nA small piece of skin may be removed.\\n\\nA skin or blood sample may be taken to create stem cells.\\n\\nOptional lumbar puncture. A needle will be inserted into the space between the bones of the back to collect fluid.\\n\\nIf participants are not eligible for current studies, they may be contacted in the future.', 'detailedDescription': 'Objectives\\n\\nThe primary objective is to evaluate patients referred with a diagnosis of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative disorders to assess patient eligibility for ongoing protocols. The secondary objective is to develop and maintain a registry of characterized patients and presymptopmatic carriers of gene mutations that cause ALS-FTD spectrum disorders. The exploratory objectives are to obtain biospecimens from clinically characterized patients to carry out laboratory-based studies aimed at understanding the molecular pathways and genetic overlap between these neurodegenerative disorders and to perform 7 tesla magnetic resonance imaging studies to identify imaging biomarkers of neurodegeneration.\\n\\nStudy population\\n\\nAdults referred with clinical diagnoses of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder. Presymptomatic carriers of genes known to cause familial FTD or ALS\\n\\nDesign\\n\\nAll participants will undergo clinical tests to confirm diagnoses and to stage disease severity, including a standard battery of tests to measure cognitive and motor functions. Participants may opt-in for research procedures such as phlebotomy, skin biopsy, leukapheresis, and lumbar puncture to obtain biospecimens for laboratory research, and magnetic resonance imaging or transcranial magnetic stimulation may be used to explore biomarkers of disease.\\n\\nOutcome measures\\n\\nClinical information will be analyzed as part of our research to identify common features and differences among participants.'}, 'conditionsModule': {'conditions': ['Frontotemporal Dementia', 'Amyotrophic Lateral Sclerosis', 'Progressive Supranuclear Palsy'], 'keywords': ['TDP-43', 'Progressive Supranuclear Palsy', 'Motor Neuron Disease', 'Frontotemporal Dementia', 'Corticobasal Syndrome', 'Natural History']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 300, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients', 'description': 'patients who are referred with a diagnosis of frontotemporal dementia, motor neuron disorder, or related adult-onset neurodegenerative disorder to assess patient eligibility for ongoing protocols'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Clinical information', 'description': 'Clinical information will be analyzed as part of our research to identify common features and differences among participants.', 'timeFrame': '10/30/2025'}]}, 'eligibilityModule': {'eligibilityCriteria': '* INCLUSION CRITERIA:\\n\\nPatients will be included if they\\n\\n* Are age 18 or older\\n* Have been given a diagnosis by a neurologist of frontotemporal dementia, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, progressive bulbar palsy, corticobasal neurodegenerative disorder OR\\n* Carry a mutation in a gene that causes familial ALS or FTD\\n\\nEXCLUSION CRITERIA:\\n\\nPatients will be excluded if they\\n\\n* Have other major neurological or medical diseases that may cause progressive weakness or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or radiculopathy or other significant neurological abnormalities.\\n* Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe\\n* Require daytime ventilator support at the time of study entry\\n* Are unable to travel to NIH\\n* Patients with pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye) will not be excluded but will not undergo magnetic resonance imaging.\\n* Patients with tattoos above the neck or permanent make up will be excluded from undergoing 7T MRI.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Adults with a diagnosis of ALS, FTD, or a related adult-onset neurodegenerative disorder', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Carol H Hoffman', 'role': 'CONTACT', 'phone': '(301) 451-1229', 'email': 'carol.hoffman@nih.gov'}, {'name': 'Justin Y Kwan, M.D.', 'role': 'CONTACT', 'phone': '(301) 496-7428', 'email': 'justin.kwan@nih.gov'}], 'overallOfficials': [{'name': 'Justin Y Kwan, M.D.', 'affiliation': 'National Institute of Neurological Disorders and Stroke (NINDS)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'National Institutes of Health Clinical Center', 'status': 'RECRUITING', 'city': 'Bethesda', 'state': 'Maryland', 'zip': '20892', 'country': 'United States', 'contacts': [{'name': 'For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)', 'role': 'CONTACT', 'phone': '800-411-1222', 'phoneExt': 'TTY8664111010', 'email': 'prpl@cc.nih.gov'}], 'geoPoint': {'lat': 38.98067, 'lon': -77.10026}}]}, 'referencesModule': {'references': [{'pmid': '26473392', 'type': 'BACKGROUND', 'citation': 'Snowden JS, Adams J, Harris J, Thompson JC, Rollinson S, Richardson A, Jones M, Neary D, Mann DM, Pickering-Brown S. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):497-505. doi: 10.3109/21678421.2015.1074700. Epub 2015 Oct 16.'}, {'pmid': '21944779', 'type': 'BACKGROUND', 'citation': 'Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M; ITALSGEN Consortium; Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68. doi: 10.1016/j.neuron.2011.09.010. Epub 2011 Sep 21.'}], 'seeAlsoLinks': [{'label': 'NIH Clinical Center Detailed Web Page', 'url': 'https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-N-0131.html'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': '.Undecided.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000003704', 'term': 'Dementia'}, {'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000057180', 'term': 'Frontotemporal Dementia'}, {'id': 'D000018888', 'term': 'Aphasia, Primary Progressive'}, {'id': 'D000020774', 'term': 'Pick Disease of the Brain'}, {'id': 'D000013494', 'term': 'Supranuclear Palsy, Progressive'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000001927', 'term': 'Brain Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D000001523', 'term': 'Mental Disorders'}, {'id': 'D000024801', 'term': 'Tauopathies'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}, {'id': 'D000057174', 'term': 'Frontotemporal Lobar Degeneration'}, {'id': 'D000001037', 'term': 'Aphasia'}, {'id': 'D000013064', 'term': 'Speech Disorders'}, {'id': 'D000007806', 'term': 'Language Disorders'}, {'id': 'D000003147', 'term': 'Communication Disorders'}, {'id': 'D000019954', 'term': 'Neurobehavioral Manifestations'}, {'id': 'D000009461', 'term': 'Neurologic Manifestations'}, {'id': 'D000001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D000009069', 'term': 'Movement Disorders'}, {'id': 'D000009886', 'term': 'Ophthalmoplegia'}, {'id': 'D000015835', 'term': 'Ocular Motility Disorders'}, {'id': 'D000003389', 'term': 'Cranial Nerve Diseases'}, {'id': 'D000010243', 'term': 'Paralysis'}, {'id': 'D000005128', 'term': 'Eye Diseases'}], 'browseLeaves': [{'id': 'M16355', 'name': 'Syndrome', 'relevance': 'LOW'}, {'id': 'M6904', 'name': 'Dementia', 'asFound': 'Dementia', 'relevance': 'HIGH'}, {'id': 'M13157', 'name': 'Paralysis', 'relevance': 'LOW'}, {'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'asFound': 'Neurodegenerative Disorders', 'relevance': 'HIGH'}, {'id': 'M28762', 'name': 'Frontotemporal Dementia', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'M20929', 'name': 'Aphasia, Primary Progressive', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'M22530', 'name': 'Pick Disease of the Brain', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'M16275', 'name': 'Supranuclear Palsy, Progressive', 'asFound': 'Progressive Supranuclear Palsy', 'relevance': 'HIGH'}, {'id': 'M2649', 'name': 'Corticobasal Degeneration', 'relevance': 'LOW'}, {'id': 'M4352', 'name': 'Aphasia', 'relevance': 'LOW'}, {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M21836', 'name': 'Neurocognitive Disorders', 'relevance': 'LOW'}, {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'}, {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}, {'id': 'M23002', 'name': 'Tauopathies', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M28756', 'name': 'Frontotemporal Lobar Degeneration', 'relevance': 'LOW'}, {'id': 'M15864', 'name': 'Speech Disorders', 'relevance': 'LOW'}, {'id': 'M10823', 'name': 'Language Disorders', 'relevance': 'LOW'}, {'id': 'M6374', 'name': 'Communication Disorders', 'relevance': 'LOW'}, {'id': 'M21826', 'name': 'Neurobehavioral Manifestations', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'M25603', 'name': 'Ganglion Cysts', 'relevance': 'LOW'}, {'id': 'M16358', 'name': 'Synovial Cyst', 'relevance': 'LOW'}, {'id': 'M4774', 'name': 'Basal Ganglia Diseases', 'relevance': 'LOW'}, {'id': 'M12029', 'name': 'Movement Disorders', 'relevance': 'LOW'}, {'id': 'M12817', 'name': 'Ophthalmoplegia', 'relevance': 'LOW'}, {'id': 'M18386', 'name': 'Ocular Motility Disorders', 'relevance': 'LOW'}, {'id': 'M6605', 'name': 'Cranial Nerve Diseases', 'relevance': 'LOW'}, {'id': 'M8271', 'name': 'Eye Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T2399', 'name': 'Frontotemporal Dementia', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'T2400', 'name': 'Frontotemporal Dementia, Ubiquitin-positive', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'T4710', 'name': 'Primary Progressive Aphasia', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'T5168', 'name': 'Semantic Dementia', 'asFound': 'Frontotemporal Dementia', 'relevance': 'HIGH'}, {'id': 'T4741', 'name': 'Progressive Supranuclear Palsy', 'asFound': 'Progressive Supranuclear Palsy', 'relevance': 'HIGH'}, {'id': 'T1606', 'name': 'Corticobasal Degeneration', 'relevance': 'LOW'}, {'id': 'T704', 'name': 'Behavioral Variant of Frontotemporal Dementia', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC11', 'name': 'Eye Diseases'}, {'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06315673', 'orgStudyIdInfo': {'id': 'STUDY00024562'}, 'organization': {'fullName': 'Milton S. Hershey Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Digital Assessment of Speech and Fine Motor Control in ALS', 'officialTitle': 'Digital Assessment of Speech and Fine Motor Control in ALS'}, 'statusModule': {'statusVerifiedDate': '2024-03', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-04-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2026-03-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-03-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-03-12', 'studyFirstSubmitQcDate': '2024-03-12', 'studyFirstPostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-03-12', 'lastUpdatePostDateStruct': {'date': '2024-03-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Andrew Geronimo', 'investigatorTitle': 'Assistant Professor, Department of Neurosurgery', 'investigatorAffiliation': 'Milton S. Hershey Medical Center'}, 'leadSponsor': {'name': 'Milton S. Hershey Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'BioSensics', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease. Patients with motor neuron disease (including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), and progressive muscular atrophy (PMA)) and age-matched healthy controls will be enrolled. Subjects will complete a speech and handwriting assessment during the study visit on a tablet computer (BioSensics LLC, Newton, MA). We will explore whether these digital biomarkers are sensitive to functional disease severity as reported by the ALS Functional Rating Scale - Revised (ALFRS-R) \\\\[1\\\\]. We will also compare assessment data between the patient and control groups.', 'detailedDescription': \"ALS is a progressive neuromuscular disease that causes weakness and inevitably affecting multiple motor processes within the body. To assess changes in functional mobility, clinicians and clinical investigators often rely on the ALS Functional Rating Scale - Revised (ALSFRS-R), a standardized 12-item questionnaire that has been in use for decades. Although thoroughly validated, this scale has received criticism for providing a coarse reflection of a patient's disease, scaling non-linearly within and across functional domains, and without the sensitivity to reflect day-to-day variability or small but meaningful changes.\\n\\nThis study includes collection of digital speech and fine motor control assessment data at a single study visit. Features extracted from this data will be compared with standard clinical disease outcome measures and also the features derived from control participant data. We will use these comparisons to explore the use of these digital assessments in capturing the range of functional changes that occur in ALS and the related motor neuron diseases of PLS and PMA that are regularly treated in the ALS clinic.\"}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis', 'Primary Lateral Sclerosis', 'Progressive Muscular Atrophy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patient', 'description': 'Individuals with diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria \\\\[2\\\\], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).', 'interventionNames': ['Behavioral: Digital Speech and Handwriting Assessment']}, {'label': 'Control', 'description': 'Individuals with no neurological or orthopedic problems that affects their speech or handwriting AND age-matched to the existing patient cohort.', 'interventionNames': ['Behavioral: Digital Speech and Handwriting Assessment']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Digital Speech and Handwriting Assessment', 'description': 'Subjects may complete all or some of these tests, depending on functional ability.\\n\\n* Handwriting battery\\n* Pattern tracing battery\\n* Speech Assessment Battery', 'armGroupLabels': ['Control', 'Patient']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Speaking rate during a standardized passage', 'description': 'Speaking rate, in words per minute, will be determined from an audio recording of a standardized reading passage.', 'timeFrame': 'baseline'}, {'measure': 'Residual on spiral tracing task', 'description': 'Handwriting tasks include tracing of a spiral. The average residual, or deviation from the target spiral (in pixels), will be determined from the handwriting file associated with the tracing task.', 'timeFrame': 'baseline'}], 'secondaryOutcomes': [{'measure': 'ALS Functional Rating Scale- Revised (ALSFRS-R)', 'description': \"The ALSFRS-R measures 12 aspects of physical function, ranging from one's ability to swallow and use utensils to climbing stairs and breathing. Each function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0.\", 'timeFrame': 'baseline'}, {'measure': 'Forced vital capacity (FVC)', 'description': 'FVC is collected at clinical appointments by a respiratory therapist. FVC is the volume of air that is forcefully expelled into a spirometer. FVC is expressed as a percentage (%) of predicted volume against an age, height, and ethnicity matched standard. The best result of three trials is used.', 'timeFrame': 'baseline'}, {'measure': 'Upper motor neuron function', 'description': 'Reflex testing is performed by the attending neurologist at clinical appointments. Bilateral biceps, triceps, and brachioradialis reflexes will be documented according to Modified Ashworth Scale grade 0 (no tone increase) to 4 (limb rigid). Total score for bilateral muscle groups ranges from 0 to 24.', 'timeFrame': 'baseline'}, {'measure': 'Strength testing', 'description': 'Strength testing is performed by the attending neurologist at clinical appointments. Bilateral deltoids, biceps, triceps, wrist extension, and interossei strength will be documented according to Medical Research Council (MRC) grade 0 (no power) to 5 (normal power). Total score for bilateral muscle groups ranges from 0 to 50.', 'timeFrame': 'baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. \\\\[Patient Group Only\\\\] Diagnosis of definite, probable, probable laboratory-supported, or possible ALS by revised El Escorial research criteria \\\\[Brooks2000\\\\], primary lateral sclerosis (PLS), or progressive muscular atrophy (PMA).\\n2. \\\\[Patient Group Only\\\\] at least minimal speech or handwriting ability\\n\\n   1. ALSFRS-R speech score of 2 (\"intelligible speech with repeating\") or greater, OR\\n   2. ALSFRS-R handwriting score of 2 (\"not all words are legible\") or greater.\\n3. \\\\[Control Group Only\\\\] Possess no neurological or orthopedic problems that affects their speech or handwriting AND age-matched to the existing patient cohort.\\n4. 18 years of age or older;\\n5. Fluent in written and spoken English.\\n\\nExclusion Criteria:\\n\\n1. Currently or previously enrolled in STUDY00013892 (NCT05271435)\\n2. Neurological or orthopedic problems (independent of their inclusionary diagnosis for the patient group) that affects their speech or handwriting\\n3. Pregnant or nursing woman\\n4. Prisoner or institutionalized individuals\\n5. Have any clinically relevant medical history of other disease or diseases that, in the opinion of the research team, exclude the subject from participation (including severe cognitive dysfunction).', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients with motor neuron disease and age- and sex-matched, neurologically-healthy controls.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Andrew Geronimo, PhD', 'role': 'CONTACT', 'phone': '7175310003', 'phoneExt': '282576', 'email': 'ageronimo@pennstatehealth.psu.edu'}]}, 'referencesModule': {'references': [{'pmid': '10540002', 'type': 'BACKGROUND', 'citation': 'Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21. doi: 10.1016/s0022-510x(99)00210-5.'}, {'pmid': '11464847', 'type': 'BACKGROUND', 'citation': 'Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. doi: 10.1080/146608200300079536. No abstract available.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Study data without identifiers may be shared with other researchers at reasonable request of the PI', 'infoTypes': ['STUDY_PROTOCOL', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'Data will become available upon publication'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000009133', 'term': 'Muscular Atrophy'}, {'id': 'D000009134', 'term': 'Muscular Atrophy, Spinal'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000001284', 'term': 'Atrophy'}, {'id': 'D000020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}, {'id': 'D000020879', 'term': 'Neuromuscular Manifestations'}, {'id': 'D000009461', 'term': 'Neurologic Manifestations'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4589', 'name': 'Atrophy', 'relevance': 'LOW'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M12090', 'name': 'Muscular Atrophy', 'asFound': 'Muscular Atrophy', 'relevance': 'HIGH'}, {'id': 'M12091', 'name': 'Muscular Atrophy, Spinal', 'asFound': 'Progressive Muscular Atrophy', 'relevance': 'HIGH'}, {'id': 'M22519', 'name': 'Pathological Conditions, Anatomical', 'relevance': 'LOW'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M22619', 'name': 'Neuromuscular Manifestations', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T5342', 'name': 'Spinal Muscular Atrophy', 'asFound': 'Progressive Muscular Atrophy', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01959373', 'orgStudyIdInfo': {'id': '2013-A00802-43'}, 'secondaryIdInfos': [{'id': '2013-22', 'type': 'OTHER', 'domain': 'AP HM'}], 'organization': {'fullName': 'Assistance Publique Hopitaux De Marseille', 'class': 'OTHER'}, 'briefTitle': 'Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis', 'officialTitle': 'Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis'}, 'statusModule': {'statusVerifiedDate': '2015-08', 'overallStatus': 'SUSPENDED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-10'}, 'primaryCompletionDateStruct': {'date': '2014-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-10-08', 'studyFirstSubmitQcDate': '2013-10-08', 'studyFirstPostDateStruct': {'date': '2013-10-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-08-21', 'lastUpdatePostDateStruct': {'date': '2015-08-24', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Assistance Publique Hopitaux De Marseille', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Amyotrophic lateral sclerosis (ALS) is characterized clinically by abnormalities of both upper motor neurons (UMN) and lower motor neurons (LMN). The presence of UMN signs is not always easy to establish. The only technique used in routine to assess the corticospinal dysfunctions is based on transcranial magnetic stimulation (TMS). However, this technique is largely dependent on LMN state and is based on artificial motor cortex activation.\\n\\nThe main objective of our study project is to evaluate a new method assessing functional changes in motor system in ALS patients. By using cortico-muscular and cortico-cortical coherences, it could be possible to show modifications in both cortico-muscular relationship and in cortical activity coordination which could be related to clinical state in ALS patients. We notably expect a decrease in cortico-muscular coherence in ALS patients. Furthermore, these analyses could provide new insights in motor system plasticity phenomena. We expect a partial covering of voluntary motor command by cortical areas adjacent to primary motor cortex. Lastly, the hypothesis that an increased proportion of voluntary motor control may be assumed by ipsilateral corticospinal tract could be tested by coherence analyses.\\n\\nCoherence analysis might be a useful method to detect corticospinal tract dysfunctions. This method has the advantage to be painless and not to use artificial stimulations as it is used in TMS.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'patients', 'type': 'EXPERIMENTAL', 'interventionNames': ['Procedure: electroencephalograms (EEG)', 'Procedure: electro-myography (EMG)']}, {'label': 'healthy volunteers', 'type': 'EXPERIMENTAL', 'interventionNames': ['Procedure: electroencephalograms (EEG)', 'Procedure: electro-myography (EMG)']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'electroencephalograms (EEG)', 'armGroupLabels': ['healthy volunteers', 'patients']}, {'type': 'PROCEDURE', 'name': 'electro-myography (EMG)', 'armGroupLabels': ['healthy volunteers', 'patients']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'recording neuronal activities', 'description': 'simultaneous recording of brain activity using electrodes attached to the scalp and muscle activities of muscles of the hands with electrodes bonded to the skin.', 'timeFrame': '12 months'}], 'secondaryOutcomes': [{'measure': 'identify plasticity phenomena', 'description': 'identify plasticity phenomena used in the cortex during the disease. The question is whether a reorganization of cortical networks could preserve, temporarily, the ability of patients to perform muscle contractions which case to determine the nature of the changes induced', 'timeFrame': '12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patient female or male, more than 18 years,\\n* Patien with a diagnosis of amyotrophic lateral sclerosis according to the El Escorial criteria of Brooks et al. 1994\\n* Patient , the beginning of the SLA date less than 12 months,\\n* Patient not having a familial form of ALS,\\n* Patient not having cancer, autoimmune disease, liver failure, severe hypertension or untreated, severe conduction disorders or uncontrolled arrhythmia\\n* Patient not having a chronic psychiatric disease, dementia.\\n* Patient with normal visual function\\n* Patients receiving social coverage\\n* Patient have read, understood and signed an informed consent after information\\n\\nExclusion Criteria:\\n\\n* Patient minor\\n* Patient with a familial form of ALS,\\n* Patient associated with severe progressive disease (cancer, autoimmune disease , liver failure )\\n* Patient (s) with chronic mental illness, dementia ,\\n* Presence of atypical clinical signs such as cerebellar ataxia , extrapyramidal signs, sensory disorders , autonomic dysfunction .\\n* Clinical signs of chronic respiratory failure or slow and / or forced less than 70% of the theoretical value or chronic hypercapnia than 45 mmHg vital capacity .\\n* Patient private freedom following a judicial or administrative decision\\n* Patient major Trust\\n* Pateinte pregnant, parturient , lactating\\n* Patient major in legal protection ( guardianship )\\n* Pateinte pregnant , parturient , lactating\\n* Patient hospital without consent\\n* Patient admitted in a health or social establishment for purposes other than research', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'LOIC MONDOLONI', 'affiliation': 'Assistance Publique Hopitaux De Marseille', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Assistance Publique Hopitaux de Marseille', 'city': 'Marseille', 'zip': '13354', 'country': 'France', 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03519880', 'orgStudyIdInfo': {'id': 'HUM00112433'}, 'organization': {'fullName': 'University of Michigan', 'class': 'OTHER'}, 'briefTitle': 'A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects', 'officialTitle': 'A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects'}, 'statusModule': {'statusVerifiedDate': '2021-04', 'overallStatus': 'TERMINATED', 'whyStopped': 'COVID-19 research restrictions', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2017-03-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-03-14', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2020-03-14', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-04-16', 'studyFirstSubmitQcDate': '2018-05-08', 'studyFirstPostDateStruct': {'date': '2018-05-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-04-05', 'lastUpdatePostDateStruct': {'date': '2021-04-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Stephen Goutman', 'investigatorTitle': 'Assistant Professor of Neurology', 'investigatorAffiliation': 'University of Michigan'}, 'leadSponsor': {'name': 'University of Michigan', 'class': 'OTHER'}, 'collaborators': [{'name': 'ALS Association', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Non-invasive ventilation (NIV) is an important therapy for patients with a number of neurological diseases. Specifically, NIV has been shown to be an effective treatment for people with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), which is a fatal, non-curable, progressive disease of the motor neurons. However, due to changes in facial structure associated with the disease, many ALS patients find that traditional NIV masks don't fit well. In this study, investigators will perform a feasibility study on NIV mask interfaces which are custom designed for each ALS patient and then manufactured via 3D printing.\", 'detailedDescription': 'Non-invasive ventilation (NIV) is an important therapy for patients with a number of neurological diseases. Specifically, for amyotrophic lateral sclerosis (ALS)--a fatal, non-curable, progressive disease of the motor neurons--NIV represents one of the most effective treatments with a survival benefit of greater than 1 year. Despite this survival advantage, and the corresponding improvement in Quality of Life (QoL), compliance with NIV can be poor. Factors contributing to poor compliance to NIV include bulbar onset disease and mask leaks. In addition to reduced adherence to therapy, elevated mask leaks can compromise the pressure adjustment algorithm in average volume assured pressure support (AVAPS) ventilation, a commonly used mode of bilevel (positive airway pressure) PAP therapy in ALS. In an effort to increase NIV compliance in subjects with neurological conditions, and specifically ALS, investigators hypothesize that a better fit achieved through 3D printed NIV mask interfaces may improve utilization by decreasing mask leaks, decreasing the required delivery pressures and improving compliance with therapy. Investigators therefore propose a feasibility study to investigate the use of 3D printing to manufacture customized NIV mask interfaces for subjects with ALS who encounter difficulty using NIV because of poorly fitting mask interfaces despite exhausting available commercial mask options.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['amyotrophic lateral sclerosis, non-invasive ventilation, mask, custom, 3D-printing']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'All trial enrollees will receive the custom-designed 3D printed non-invasive ventilation mask interface.', 'primaryPurpose': 'DEVICE_FEASIBILITY', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'There is no masking.'}}, 'enrollmentInfo': {'count': 5, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Custom Mask Interface', 'type': 'EXPERIMENTAL', 'description': 'Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.', 'interventionNames': ['Device: Custom Mask Interface']}], 'interventions': [{'type': 'DEVICE', 'name': 'Custom Mask Interface', 'description': 'Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.', 'armGroupLabels': ['Custom Mask Interface']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Average number of hours the custom NIV mask interface is used per night', 'description': 'Average number of hours the custom NIV mask interface is used per night', 'timeFrame': '1 month'}, {'measure': 'Leak parameters from device', 'description': 'Average minutes in large leak or leak measured from the device in liters per minute and averaged over the month', 'timeFrame': '1 month'}, {'measure': 'Tidal volume measurements', 'description': '(average measured tidal volume/average set tidal volume)\\\\*100%', 'timeFrame': '1 month'}], 'secondaryOutcomes': [{'measure': 'Interviews with subjects regarding their experience with the custom mask Qualitative assessment of custom NIV mask efficacy', 'description': 'Interviews with subjects regarding their experience with the custom mask', 'timeFrame': '1 month'}], 'otherOutcomes': [{'measure': 'ALS Depression Inventory-12 (ADI-12)', 'description': 'Depression Scale. Scales: For each question, the following is selected: \"I fully agree\", \"I agree\", \"I don\\'t agree\", \"I do not agree at all\"', 'timeFrame': '1 month'}, {'measure': 'ALS Functional Rating Scale, Revised (ALSFRS-R)', 'description': \"Functional Rating Scale. Scales: Customized for each question, but 4 is the maximum and generally means 'normal', and 0 represents significant impairment.\", 'timeFrame': '1 month'}, {'measure': 'ALS Specific Quality of Life-20 (ALSSQOL20)', 'description': 'Quality of Life Scale. Scales: For each question, 1-10 is selected, where 10 means \"extremely\" and 0 means \"not at all\".', 'timeFrame': '1 month'}, {'measure': 'Epworth Sleepiness Scale (ESS)', 'description': 'Sleepiness Scale. Scales: 3 means \"high chance of dozing\", 2 means \"moderate chance of dozing\", 1 means \"slight chance of dozing\", and 0 means \"would never doze\".', 'timeFrame': '1 month'}, {'measure': 'PROMIS Neuro-Quality of Life Fatigue Scale', 'description': 'Fatigue Scale. Scales: For each question, \"Always\" (5), \"Often\" (4), \"Sometimes\" (3), \"Rarely\" (2), and \"Never\" (1) is selected.', 'timeFrame': '1 month'}, {'measure': 'PROMIS Neuro-Quality of Life Sleep Disturbance Scale', 'description': 'Sleep Disturbance Scale. Scales: For each question, \"Always\" (5), \"Often\" (4), \"Sometimes\" (3), \"Rarely\" (2), and \"Never\" (1) is selected.', 'timeFrame': '1 month'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Age greater than 18\\n2. Ability to communicate in English\\n3. Diagnosis of ALS\\n4. Subject followed in the ALS Clinic at University of Michigan\\n5. Current use of NIV.\\n6. Problematic mask leak defined as one of the following:\\n\\n   A. A clinical complaint of mask leak impeding use of PAP AND PAP use \\\\<6 hours per night AND/OR B. Average percentage of the night in large leak on download of \\\\>10% (AVAPS)\\n7. At least 1 month of NIV use\\n\\nExclusion Criteria:\\n\\n1. Subjects successfully using a commercially available mask without objective or subjective leak with good compliance (average use \\\\>6 hours per night)\\n2. Silicone allergy', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Stephen A Goutman, MD', 'affiliation': 'University of Michigan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Michigan Medicine', 'city': 'Ann Arbor', 'state': 'Michigan', 'zip': '48109', 'country': 'United States', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01508962', 'orgStudyIdInfo': {'id': 'PRESS-ALS'}, 'organization': {'fullName': 'University of Miami', 'class': 'OTHER'}, 'briefTitle': 'PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis', 'officialTitle': 'PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis', 'acronym': 'PRESS-ALS'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-11'}, 'primaryCompletionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2012-01-09', 'studyFirstSubmitQcDate': '2012-01-11', 'studyFirstPostDateStruct': {'date': '2012-01-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-02-28', 'lastUpdatePostDateStruct': {'date': '2024-03-01', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Michael Benatar', 'investigatorTitle': 'Professor of Neurology', 'investigatorAffiliation': 'University of Miami'}, 'leadSponsor': {'name': 'University of Miami', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of PRESS-ALS is to study the earliest manifestations of disease in people with early ALS in whom some areas of the body are not yet affected.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Disease onset', 'Disease progression']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Healthy individuals (controls)'}, {'label': 'Individuals affected with ALS (sporadic or familial)'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phenoconversion', 'timeFrame': 'Every three months over the course of one year'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria\\n\\nALS group:\\n\\n* Subject is a male or female, aged at least 18 years.\\n* Subject is affected with ALS (familial or sporadic).\\n* Subject has at least one limb in which there is no symptomatic upper and lower motor neuron dysfunction.\\n* Subject is willing and able to comply with all study procedures.\\n* Subject agrees to provide signed and dated informed consent form.\\n\\nControl group:\\n\\n* Subject is a male or female, aged at least 18 years.\\n* Subject is not affected with ALS or an ALS-related disorder.\\n* Subject does not have a family history (i.e., at least 2 biological relatives) of ALS or an ALS-related disorder.\\n* Subject is willing and able to comply with all study procedures.\\n* Subject agrees to provide signed and dated informed consent form.\\n\\nExclusion Criterion\\n\\n• Any condition or situation which, in the PI's opinion, could confound the biomarker data or may interfere significantly with the individual's participation and compliance with the study protocol, including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'People affected with ALS (either familial or sporadic) and healthy controls', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'University of Miami', 'city': 'Miami', 'state': 'Florida', 'zip': '33136', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Related Info', 'url': 'http://als-research.org'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M20559', 'name': 'Disease Progression', 'relevance': 'LOW'}, {'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06206629', 'orgStudyIdInfo': {'id': '69HCL23_1291'}, 'organization': {'fullName': 'Hospices Civils de Lyon', 'class': 'OTHER'}, 'briefTitle': 'Contralateral R1 in Amyotrophic Lateral Sclerosis', 'officialTitle': 'Evaluation of Contralateral R1 Component of the Blink Reflex in Patients With Amyotrophic Lateral Sclerosis', 'acronym': 'MOTOBLINK'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-02-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-02-15', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-02-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-01-04', 'studyFirstSubmitQcDate': '2024-01-04', 'studyFirstPostDateStruct': {'date': '2024-01-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-15', 'lastUpdatePostDateStruct': {'date': '2024-02-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hospices Civils de Lyon', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting both upper and lower motor neurons. Electroneuromyography is an important tool for the diagnosis. Previous studies have shown that different components of the blink reflex, such as the latencies of homo- and contralateral R2 responses can be affected. Studies have found that a contralateral R1 component can appear in neurological diseases with affection of the central nervous system especially upper motor neuron, such as HTLV1 infection. Thus, you aim to determine if a contralateral R1 component could be present in ALS.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['Amyotrophic lateral sclerosis', 'ALS', 'Electroneuromyography', 'ENMG']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ALS patients', 'description': 'Patients with ALS (Awaji criteria)', 'interventionNames': ['Diagnostic Test: blink reflex evaluation']}, {'label': 'Non-ALS patients', 'description': 'Patients referred to the neurophysiology unit for a suspicion of ALS du to motor weakness, but in whom the diagnosis is ruled out.', 'interventionNames': ['Diagnostic Test: blink reflex evaluation']}, {'label': 'Healthy volunteers', 'description': 'Healthy volunteers who will undergo a blink reflex evaluation on ENMG.', 'interventionNames': ['Diagnostic Test: blink reflex evaluation']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'blink reflex evaluation', 'description': 'A blink reflex evaluation will be performed in all subjects', 'armGroupLabels': ['ALS patients', 'Healthy volunteers', 'Non-ALS patients']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Presence of a contralateral R1 component on blink reflex evaluation.', 'description': 'A blink reflex evaluation will be performed in all subjects : Blink reflex will be recorded with surface electrodes placed medially over the lower part of the eyelid, on the orbicularis oculi muscle, with a reference electrode 2 cm laterally. Stimuli will be delivered to the supraorbital nerve by surface electrodes with an intensity required to generate a consistent homolateral R1 response.\\n\\nA contralateral R1 component will be defined as an early compound muscle action potential recorded in the contralateral orbicularis oculi muscle.', 'timeFrame': 'Day 1'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\nFor patients\\n\\n* Aged 18 to 99 years old\\n* Referred for suspected motor neuromuscular disease\\n* Collection of non-opposition\\n\\nFor healthy subjects:\\n\\n* Aged 18 to 99 years old\\n* Absence of any neurological pathology\\n* Collection of non-opposition\\n\\nExclusion Criteria:\\n\\n* Previous damage linked to another cause of the cranial nerves\\n* Prior brainstem lesions\\n* Persons deprived of liberty by a judicial or administrative decision\\n* Patient under judicial protection, unable to express consent', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '99 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients referred to the neurophysiology unit from the Hospices civils de Lyon, for a suspicion of motor neuron disease.\\n\\nAnd healthy volunteers for the third group.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Hôpital neurologique Pierre Wertheimer', 'status': 'RECRUITING', 'city': 'Bron', 'state': 'Rhone', 'zip': '69500', 'country': 'France', 'contacts': [{'name': 'Antoine PEGAT, Dr', 'role': 'CONTACT', 'phone': '0472118062', 'phoneExt': '+33', 'email': 'antoine.pegat@chu-lyon.fr'}, {'name': 'Antoine Pegat, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'CHU de Nantes', 'status': 'RECRUITING', 'city': 'Nantes', 'zip': '44093', 'country': 'France', 'contacts': [{'name': 'Yann Pereon, Pr', 'role': 'CONTACT', 'phone': '0240083616', 'phoneExt': '+33', 'email': 'Yann.pereon@univ-nantes.fr'}, {'name': 'Yann Pereon, Pr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01494480', 'orgStudyIdInfo': {'id': '20111207ALS'}, 'organization': {'fullName': 'General Hospital of Chinese Armed Police Forces', 'class': 'OTHER'}, 'briefTitle': 'The Clinical Trial on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis', 'officialTitle': 'The Clinical Study on the Use of Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis'}, 'statusModule': {'statusVerifiedDate': '2012-06', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-03'}, 'primaryCompletionDateStruct': {'date': '2013-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2015-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2011-12-07', 'studyFirstSubmitQcDate': '2011-12-15', 'studyFirstPostDateStruct': {'date': '2011-12-19', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2012-06-18', 'lastUpdatePostDateStruct': {'date': '2012-06-20', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'General Hospital of Chinese Armed Police Forces', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'Patients with Amyotrophic Lateral Sclerosis (ALS) typically endure a progressive paralysis due to the continued loss of motoneurons that leads them to death in less than 5 years. No treatment has changed its natural history. Intrathecal injection of umbilical cord mesenchymal stem cells can secret trophic factors that keep the motorneurons functional. The investigators have designed a phase I/II clinical trial to check the feasibility of this approach in humans.', 'detailedDescription': 'A total of 30 diagnosed ALS patients. The patients would got these symptoms such as gait difficulty and tremor, hand incoordination or speech difficulties.'}, 'conditionsModule': {'conditions': ['Amyotrophic Lateral Sclerosis'], 'keywords': ['ALS', 'stem cell']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'stem cell transplantation', 'type': 'EXPERIMENTAL', 'description': 'After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.', 'interventionNames': ['Procedure: stem cell transplantation']}], 'interventions': [{'type': 'PROCEDURE', 'name': 'stem cell transplantation', 'description': 'after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.', 'armGroupLabels': ['stem cell transplantation'], 'otherNames': ['the stem cell treatment of ALS']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Nerve functional evaluation', 'description': '1. Medical Research Council scale：To determine the strength of bilateral little finger abductor muscle and anterior tibial.\\n2. To evaluate the situation of upper motor neuron impairment through the Ellis reflex scale\\n3. The severity evaluation: NorrisALS score and ALS functional rating scale, ALSFRS\\n4. Speed of disease progression by the following formula：Progress rate = (40-ALSFRS score) / course\\n5. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI) and memory (Mini Mental State Examination)', 'timeFrame': 'within one week before,1month,6months,12months and 24months after transplantation'}, {'measure': 'Forced vital capacity', 'description': 'vital capacity(VC）、forced vital capacity( FVC）、forced expiratory volune(FEV1）、FEV1/FVC、maximal voluntary ventilation(MVV）、peak expiratory flow(PEF）', 'timeFrame': 'within one week before,1month,6months,12months and 24months after transplantation'}], 'secondaryOutcomes': [{'measure': 'Blood test', 'description': 'white blood cell、neutrophilic granulocyte、leukomonocyte；glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK)；acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin；lymphotoxin(LCT). Tumor markers , Lymphocytes classification, cholesterol total、Triglyceride、low density lipoprotein、Glycosylated serum protein glycosylated hemoglobin、Islet function，Na+、K+', 'timeFrame': 'within one week before,1month,6months,12months and 24months after transplantation'}, {'measure': 'Urinal test', 'description': 'proteinum、akaryocyte、α1- microglobulin、β2- microglobulin. CSF test:：IgA, IgG quantitation', 'timeFrame': 'within one week before,1month,6months,12months and 24months after transplantation'}, {'measure': 'Electrophysiology examination', 'description': 'motor evoked potential(MEP)、nerve conduction and electromyologram(EMG)', 'timeFrame': 'within one week before,1month,6months,12months and 24months after transplantation'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Diagnose established following the World Federation of Neurology criteria\\n* More than 6 and less than 36 months of evolution of the disease\\n* Medullar onset of the disease\\n* More than 20 and less than 65 years old\\n* Forced Vital Capacity equal or superior to 50%\\n* Total time of oxygen saturation \\\\<90% inferior to 2% of the sleeping time\\n* Signed informed consent\\n\\nExclusion Criteria:\\n\\n* Neurological or psychiatric concomitant disease\\n* Need of parenteral or enteral nutrition through percutaneous endoscopic gastrostomy or nasogastric tube\\n* Concomitant systemic disease\\n* Treatment with corticosteroids, immunoglobulins or immunosuppressors during the last 12 months\\n* Inclusion in other clinical trials\\n* Unability to understand the informed consent', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '65 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'YiHua An', 'affiliation': \"Chinese People's Armed Police Force\", 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Yihua An', 'city': 'Beijing', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-03-28'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000016472', 'term': 'Motor Neuron Disease'}, {'id': 'D000000690', 'term': 'Amyotrophic Lateral Sclerosis'}, {'id': 'D000012598', 'term': 'Sclerosis'}], 'ancestors': [{'id': 'D000010335', 'term': 'Pathologic Processes'}, {'id': 'D000019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D000009422', 'term': 'Nervous System Diseases'}, {'id': 'D000009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D000013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D000002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D000057177', 'term': 'TDP-43 Proteinopathies'}, {'id': 'D000057165', 'term': 'Proteostasis Deficiencies'}, {'id': 'D000008659', 'term': 'Metabolic Diseases'}], 'browseLeaves': [{'id': 'M15415', 'name': 'Sclerosis', 'asFound': 'Sclerosis', 'relevance': 'HIGH'}, {'id': 'M18879', 'name': 'Motor Neuron Disease', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M4024', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M12411', 'name': 'Neuromuscular Diseases', 'relevance': 'LOW'}, {'id': 'M15915', 'name': 'Spinal Cord Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M28759', 'name': 'TDP-43 Proteinopathies', 'relevance': 'LOW'}, {'id': 'M28747', 'name': 'Proteostasis Deficiencies', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'T4699', 'name': 'Primary Lateral Sclerosis', 'asFound': 'Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'T349', 'name': 'Amyotrophic Lateral Sclerosis', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}], 'nextPageToken': 'NF0g5JqFk_Ug'}\n"
     ]
    }
   ],
   "source": [
    "query = \"Amyotrophic Lateral Sclerosis\"\n",
    "result = fetch_studies(query)\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_study_info(study):\n",
    "    title = study['protocolSection']['identificationModule']['officialTitle']\n",
    "    description = study['protocolSection']['descriptionModule']['detailedDescription']\n",
    "    \n",
    "    info = f'''Title: {title} \\n description: {description}\n",
    "    '''\n",
    "    return info\n",
    "\n",
    "def get_patient_info(patient):\n",
    "    condition = patient['profile'].condition\n",
    "    age = patient['profile'].age\n",
    "    description = patient['profile'].profile\n",
    "    gender = patient['profile'].gender\n",
    "    country = patient['profile'].country\n",
    "    info =  f'''condition: {condition} \\n age: {age} \\n description: {description} \\n gender: {gender} \\n country: {country}'''\n",
    "\n",
    "    return info\n",
    "\n",
    "def create_promt(patient, study):\n",
    "    study_info= get_study_info(study)\n",
    "    patient_info= get_patient_info(patient)\n",
    "    promt = f'''You are an expert doctor and you need to determine the eligibility of the patient for the given trail based on the information of the paitient and the train:\n",
    "    Patient information\n",
    "    {patient_info}\n",
    "    Trial Information\n",
    "    {study_info}\n",
    "    Predict whether the patient is eligible/uneligible/uncertain\n",
    "    Only return the category\n",
    "    '''\n",
    "    return promt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'briefSummary': 'Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of only three to five years. The disease is characterized by pathological accumulations of a protein called TDP-43, which can be found large cortical and sub-cortical areas of post-mortem ALS brains.\\n\\nNo causal treatment for this condition is known to date, and there is a large unmet need to develop new strategies in order to halt or slow down its progression.\\n\\nThe aim of this study is to test the safety and tolerability of Tideglusib, a treatment that is already in clinical trials for other neuromuscular conditions, in patients with ALS. It is assumed that this drug may have a significant therapeutic benefit in this population due to his mode of action: In the ALS mouse model, Tideglusib decreases significantly the amount of accumulated TDP-43 proteins within the cells.'}"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study2 = result['studies'][0]\n",
    "study2['protocolSection']['descriptionModule']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Title: Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) \\n description: It is known that nerve cells called motor neurons die in the brains and spinal cords of people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is unknown. Researchers think that increased levels of a chemical called \"glutamate\" may be related to the cell death. For this reason researchers want to study drugs that decrease glutamate levels near nerves. Ceftriaxone-a semi-synthetic, third generation cephalosporin antibiotic-may increase the level of a protein that decreases glutamate levels near nerves. Studies of ceftriaxone in the laboratory suggest that it may protect motor neurons from injury.\\n\\nCeftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS.\\n\\nA total of 600 eligible people with ALS will be enrolled in this multi-center research study. Participants will be randomly assigned to receive treatment with ceftriaxone (2/3 of participants) or placebo (1/3 of participants) for at least 12 months.\\n\\nThe study consists of three stages. The first stage, which has completed enrollment, will look at whether ceftriaxone enters the cerebrospinal fluid (the fluid that surrounds the spinal cord, also called CSF) in amounts that are high enough to be of possible benefit. The second stage, which has also completed enrollment, will look at the safety and side effects of the study drug when taken daily for at least 20 weeks. The study is currently enrolling subjects for the third stage, which began in Spring 2009, and will determine whether the study drug prolongs survival and slows decline in function due to ALS.\\n    '"
      ]
     },
     "execution_count": 105,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_study_info(study2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
